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EXECUTIVE SUMMARY 
BACKGROUND 
This report summarizes the findings of an allocative efficiency analysis to support 
Togo’s national HIV response. Togo has recently drafted a National HIV Strategic Plan 
(2016–20) and is preparing a new Global Fund concept note (2018–20). The 
Government of Togo would like to mobilize additional resources, including domestic and 
private resources, for comprehensive HIV services to respond to the goals of the national 
HIV Strategic Plan. To assure that the resources that have been, or will be, mobilized are 
used in the most efficient way, and to determine the allocation of 
resources that brings the greatest health benefit, the Government 
requested the World Bank to conduct this allocative efficiency analysis 
(Section 1), using the Optima mathematical model (Section 2–9 and 
Annexes). 
Togo is a low-income country with an estimated population of 7.12 
million in 2014. Togo’s Human Development Index ranks 166 out of 188 
countries, with an index of 0.473, similar to Sudan, Benin and Uganda. 
GDP per capita was USD 625 in 2014, an increase of 11% from 2011. The 
three leading causes of DALYs for all age groups in 2013 were malaria 
(14%), lower respiratory tract infections (9%) and HIV/AIDS (9%)1.  Of 
these, HIV/AIDS had the highest increase since 1990 (885%).  Togo has 
a mature, mixed HIV epidemic with an estimated prevalence of 2.5% 
among males and females (15–49 years) in 2014, but with significant 
disparities between gender, regions and key populations. Considering the high burden of 
disease attributable to HIV, the HIV response remains a critical component of health 
service delivery.  
Togo has a very large ARV treatment gap, in 2014 it was estimated that only 33% of the 
110,400 PLHIV were on ART. Togo’s ART coverage is the 23rd lowest in Sub Saharan 
Africa2. A low ART coverage and a low proportional spent on ART is characteristic of the 
HIV responses in West and Central Africa. According to UNAIDS, People living with HIV 
in Eastern and Southern Africa are more likely to obtain treatment services than people 
in Western and Central Africa3. In the West Africa Region, 79% of people who were 
estimated to be eligible for treatment under the 2013 WHO guidelines were not 
receiving antiretroviral therapy as of December 2012, compared to 59% in East and 
Southern Africa. Similarly, only 34% of HIV spending in the region went for spending for 
care and treatment, compared to 54% in East and Southern Africa and 55% globally.  
Togo’s spending on health is one of the highest in West and Central Africa.  According to 
WHO estimates for 2013, total health spending as a percentage of GDP in Togo was 9%, 
                                                               
1  http://www.healthdata.org/Togo. 
2  Estimated ART coverage among PLHIV in low and middle income country, Africa region WHO 2013  
http://gamapserver.who.int/gho/interactive_charts/hiv/art/atlas.html. 
3  UNAIDS, Access To Antiretroviral Therapy In Africa, Status Report On Progress Towards The 2015 Targets; 
UNAIDS Geneva. 
Togo’s spending 
on health is one of 
the highest in 
West and Central 
Africa, but it 
remains 
insufficient to 
cover a very large 
treatment gap.  
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an increase of more than 60% since 2000. In the same year, per capita health 
expenditure was USD 54, a four-fold increase since 2000, and 52% of health expenditure 
was funded from public sources.  Government health expenditure has increased by more 
than 80% since 2000, while out-of-pocket spending has decreased from 63% to 41% of 
total health expenditure. 
The HIV response has remained heavily dependent on donors’ contribution. Total HIV 
spending in Togo increased by nearly 50% between 2006–14.  During the same period, 
public funding nearly tripled and international funding has increased by approximately 
30%.  The Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) has been 
the country’s major international donor, contributing around 60% of all donor funds in 
2014. In 2014, the total funding for Togo’s HIV response was approximately USD 21 
million, of which 75% was financed from international donors and the remainder was 
funded by domestic sources.  In 2014, 12% of domestic funding was financed from 
private sources, with household contributions through out-of-pocket user-fees 
representing approximately 80% of private spending. 
After consultation with key stakeholders and in collaboration with the steering 
committee of this study, the following specific questions were set for the optimization 
analysis: 
 What are the expected trends in the epidemic if current spending volume and 
patterns are maintained?  
 What is the impact of past and current spending? 
 What can be improved by optimizing the allocation of current funding? 
 What is the expected future impact of different policy or program implementation 
scenarios, including the impact of reaching UNAIDS’ 90/90/90 goals, and 
Attaining 90% PMTCT coverage? 
 How much will it cost to achieve proposed National HIV Strategic Plan targets? 
 What are the long-term financial commitments to HIV services for PLHIV? 
METHODS 
The analysis was conducted using Optima, which is an epidemiological and economic 
model of HIV transmission with a resource optimization feature (Section 2 and Annex). 
For the analysis, the inputs into the Optima model were gathered through a 
comprehensive literature review and key parameters were defined using a participatory 
consultation of key stakeholders. Local demographic, epidemiological and programmatic 
data were used to populate the model. Population data for key populations (FSW, MSM, 
PWUD, Prisoners) were extrapolated based on the available local size estimation. Cost 
and expenditure estimates were derived from the National AIDS Spending Assessment 
(NASA). 
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KEY FINDINGS  
 Under current conditions, assuming stable behavior and program coverage in 
absolute numbers, the number of PLHIV is predicted to increase by 24% 
from 110,400 in 2014 to 136,300 by 2030.  New infections are predicted to 
increase 57% from 6,300 per year in 2014 to 9,900 per year in 2030.  Deaths 
are predicted to increase 31% from 4,400 per year in 2014 to 5,700 per year 
by 2030.   
 If current conditions and funding levels are maintained, HIV prevalence is 
expected to stabilize in all key populations between 2014 and 2030. Among 
children, male youth and female youth in the general population, prevalence is 
estimated to stabilize at low levels between 2014 and 2030. Prevalence is also 
expected to stabilize among men and women aged 25-49 years in the general 
population, but at higher levels.   
 At the end of 2014, there was a large treatment gap in Togo with only 33% of 
PLHIV receiving treatment. This treatment gap is typical of the HIV response in 
West and Central Africa where, on average, only 21% of PLHIV eligible for 
treatment under the WHO 2013 guidelines were receiving antiretroviral therapy 
as of December 2012. 
 The HIV allocative efficiency analysis using Optima confirmed that the current 
annual budget of USD 20.8 million was close to being optimally allocated, with 
limited gains to be made from reallocation between the different interventions 
and population groups. However, it should be noted that the optimization 
doesn’t take into account indirect costs which are considered fixed. If all indirect 
costs were reduced by 25%, then 16,900 more PLHIV might be placed onto 
treatment.  This could avert approximately 19,900 new infections and 15,400 
deaths by 2030.  As management costs make up a large proportion of indirect 
costs, reducing management costs by 25% might enable an extra 10,600 people 
to be put onto treatment, thus averting 9,900 deaths and 11,000 new infections 
by 2030.  
 The current (2014) annual budget of USD 20.8 million will not be enough 
to reduce incidence and deaths by 50%.  In order for Togo to reduce 
incidence and deaths by 50% by 2020, an annual budget envelope of 
approximately USD 39.2 million is required (88% increase on current budget). 
 Being even more ambitious, meeting UNAIDS goals of 90-90-90 will 
require additional HIV funding during the 2016 to 2020 HIV strategy period.  
Achieving 90-90-90 targets would cost an estimated USD 93.7 million between 
2016 and 2020 for treatment, and USD 3.2 million for testing, at 2014 unit costs, 
in real terms.  Meeting 90-90-90 targets could avert an estimated 63,400 
(56%) new infections by 2030 and 47,900 (68%) deaths compared to 
current coverage.  
 This implies that HIV financing needs to be increased (either through 
domestic or international sources) to cover treatment gaps and sustain other 
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comprehensive, harm reduction oriented prevention services for key 
populations.  
 Alternatively, one way to expand the total budget available for the 
programmatic epidemic response may be through the reduction of indirect costs 
(e.g. management costs).  Future technical and production efficiency 
analyses should explore ways to reduce costs without compromising the 
quality of care. 
 PMTCT programs also remain critical, both for preventing new infections 
among children, and increasing testing and treatment coverage for females aged 
15-49 years.  If 90% coverage of PMTCT was obtained by 2020, this could avert 
3,000 (35%) of new infections among children. 
CONCLUSIONS 
The Togolese government has responded effectively to a complex, mixed 
HIV epidemic.  The government’s opportunities for optimization and better 
allocation of current HIV spending to further minimize HIV incidence, 
prevalence and HIV-related deaths are minimal. 
The findings highlight however a significant treatment gap, and in this context, 
argue strongly for additional funding, optimally allocated, to achieve 90-90-90 
targets and respond most effectively to this epidemic. Effective ART scale-up is 
needed and coverage must be increased if global targets are to be met.  
In order to reduce the treatment gap, whilst ensuring additional funding 
for non-ART HIV programs for key populations, in particular FSW which 
are a key driver of the epidemic, a series of concomitant actions are 
required: reduced spending on general prevention programs targeting low-risk 
population, a larger budget envelope, prioritization of spending on core 
programs, reduced spending on indirect programs where feasible, technical 
efficiency gains, investment from budgets not earmarked for HIV that benefit 
from the broader public health impacts of key population programs.  
In order to reduce incidence and deaths by 50%, resources should be shifted 
from prevention programs targeting the general low risk population to non-ART 
key population programs, ART and PMTCT.  
Key population HIV programs would benefit from fully integrating ART 
initiation and adherence.  The model recommends a proportionately higher 
increase of spending of key populations within PLHIV to be put onto treatment. 
Additional domestic resources will be needed to sustain the HIV response.  
Funding for HIV in Togo has increased since 2007.  However, excluding ART, 
preventive programs and programs targeted at key populations are primarily 
funded by international donors.  As such, the withdrawal of international 
funding without a concurrent increase in domestic resources would have a 
significant negative impact on the HIV epidemic in Togo.   
1
2
3
4
5 
6
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 Greater technical efficiency in spending might be achieved through 
strategies to reduce the average spend per person reached.  This is 
particularly true for indirect spending.  Care should be taken however, that these 
strategies do not compromise the quality of prevention or treatment and further 
analyses of technical efficiency are needed before more robust conclusions can 
be reached. 
All the results from this study point towards the conclusion that Togo 
currently doesn’t have the appropriate resources to achieve its targets and 
that optimization gains alone cannot close this gap.  
Figure E 1 Comparing the allocation of 2014 annual spending against the optimal allocation to 
reduce deaths and incidence by 50% 
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1 BACKGROUND: WHY ALLOCATIVE 
EFFICIENCY ANALYSIS NOW? 
1.1 POPULATION, WEALTH AND HUMAN 
DEVELOPMENT IN TOGO 
Togo is a low-income country with an estimated population of 7.12 million in 2014.  The 
population has increased rapidly from 4.87 million in 2000, at an average of 2.7% per 
year4, giving Togo the 17th highest population growth in the world5.   
Togo’s Human Development Index ranks 166 out of 188 countries, with an index of 
0.473, similar to Sudan, Benin and Uganda6 GDP per capita was USD 625 in 20147, an 
increase of 11% from 2011.   
Togo shares a border with Burkina Faso, Ghana, and Benin and is situated along the 
Abidjan-Lagos Transport Corridor, which plays an important role in the HIV epidemic. 
1.2 TOGO’S HEALTH AND HEALTH FINANCING 
CONTEXT 
1.2.1 BURDEN OF DISEASE 
Life expectancy in 2013 in Togo was 61.1 years for males and 64.7 years for females, an 
increase from 57.4 years and 59.7 years in 1990 respectively8.  Togo’s overall burden of 
disease is characterized by a mix of significant causes of morbidity and mortality 
(Figure 1.1).  There is a continued contribution of neonatal and child mortality to the 
overall number of disability adjusted life years (DALYs). The three leading causes of 
DALYs for all age groups in 2013 were malaria (14%), lower respiratory tract infections 
(9%) and HIV/AIDS (9%)9.  Of these, HIV/AIDS had the highest increase since 1990 
(885%).  Considering the high burden of disease attributable to HIV, the HIV response 
remains a critical component of health service delivery. 
  
                                                               
4  http://data.worldbank.org/country/togo 
5  https://www.cia.gov/library/publications/the-world-factbook/rankorder/2002rank.html 
6  http://data.un.org/DocumentData.aspx?id=364 
7  World Bank Development indicators World Bank 
8  http://www.healthdata.org/Togo 
9  http://www.healthdata.org/Togo 
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Figure 1.1 Cause Specific Disability adjusted life years (DALYs) by age, 201010 
  
1.2.2 HEALTH CARE FINANCING AND EXPENDITURE 
Togo has a mixed health financing system funded from both public and private sources.  
The main sources of financing are government contributions, out of pocket payments, 
compulsory social health insurance (SHI) contributions and voluntary private insurance 
contributions.  Compulsory social health insurance, introduced in 2012, covers only 
public-sector workers who account for 10% of the population.  A number of private 
health insurance companies similarly cover only a minority of the population, mainly 
from higher-income groups11,12 
Togo’s spending on health is one of the highest in West and Central Africa (WCA) (see 
Figure 1.2).  According to WHO estimates for 201313, total health spending as a 
percentage of GDP in Togo was 9%, an increase of more than 60% since 2000 (see Table 
1.1).  In the same year, per capita health expenditure was USD 54, a four-fold increase 
since 2000 (see Table 1.1), and 52% of health expenditure was funded from public 
sources (see Table 1.1).  Government health expenditure has increased by more than 
80% since 2000, while out-of-pocket spending has decreased from 63% to 41% of total 
health expenditure (see Table 1.1). 
 
  
                                                               
10  http://vizhub.healthdata.org/gbd-compare/patterns 
11  Togo Country Cooperation Strategy brief,,2014 
12  IOM Country Fact Sheet, 2014. 
13  Source: WHO National Health Accounts Database (http://apps.who.int/nha/database/Select/Indicators/en) 
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Table 1.1 Trends in health expenditure in Togo, 2000–201314 
INDICATOR  2000 2005 2010 2011 2012 2013 
GDP (current prices, US$, millions) 1,294 2,110 3,193 3,688 3,882 4,306 
Total health expenditure (US$, millions) 69 139 251 295 320 371 
Total health expenditure (US$ per capita) 14 25 40 46 48 54 
Total health expenditure as a percentage of 
GDP 
5 7 8 8 8 9 
Government health expenditure as a 
percentage of total health expenditure  
29 29 48 47 51 52 
Private health expenditure as a percentage of 
total health expenditure 
71 71 52 53 49 48 
Government health expenditure as a 
percentage of total government expenditure 
8 10 15 15 15 15 
External resources for health as a percentage 
of total health expenditure  
6 19 17 16 15 6 
 Social security expenditure on health as a 
percentage of total government expenditure 
12 10 6 6 6 6 
Out-of-pocket health expenditure as a 
percentage of total health expenditure 
63 60 44 45 42 41 
Source: Authors 
Figure 1.2 Total expenditure on health as a % of GDP in West and Central African countries, 2013, 
WHO estimates 
 
                                                               
14 Source: WHO National Health Accounts Database (http://apps.who.int/nha/database/Select/Indicators/en), accessed 
20 April 2016. 
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1.3 THE HIV EPIDEMIC IN TOGO 
1.3.1 OVERVIEW OF HIV EPIDEMIC 
Togo has a mature, mixed HIV epidemic with an estimated prevalence of 2.5% among 
males and females (15-49 years) in 201415.  Significant disparities between gender, 
regions and key populations exist.  Estimated prevalence is higher amongst women 
(3.1%) than men aged 15-49 (1.7%)16.  Prevalence is also higher in the coastal regions 
(Lome 3,4%, Maritime 3%) than the northern regions (Kara 1.8%, Savane 0.3%), and in 
urban areas (3.5%) compared to rural areas (1.5%)17.  Population size and HIV 
prevalence for key populations at higher risk of HIV exposure are outlined in Table 1.2.  
Prevalence is higher among certain key populations such as FSW (11.7%)18, MSM 
13.0%19, prisoners (4.3%)20, drug users (5.5%)21 and military (3.8%)22.  Within the drug 
user population in Togo, injecting drug users make up 2.8%, making sexual transmission 
a higher risk factor than injecting drug use among this population23. 
1.3.2 HIV INCIDENCE TRENDS 
The Optima model, which will be described in more detail in the next section, estimates 
that the highest number of new infections transmitted in 2014 were by males aged 25-
49 years (39%), while the largest number of new infections acquired in 2014 were 
among females aged 25-49 years (49%), followed by 25-49 year old males (26%), and 
female youth (15%) (Figures 1.3 and 1.4).  These findings are supported by other 
studies in the region24, which suggests that the impact of networks between older men 
and young females plays an important role in the HIV transmission dynamics.    
                                                               
15  National HIV Strategic Plan draft 2016-2020, based on Spectrum/EPP 
16  Rapport d’activite sur la riposte au VIH/Sida au Togo Juin 2015 
17  Rapport d’activite sur la riposte au VIH/Sida au Togo Juin 2015 
18  FSW BBS survey 2015 
19  MSM BBS survey 2015 
20  Programme National de Lutte contre le Sida et les IST, 2011. Enquête comportementale et de séroprévalence 
du VIH chez les prisonniers Togo en 2011 
21  Programme National de Lutte contre le Sida et les IST, 2011. Enquête comportementale et de séroprévalence 
du VIH chez les utilisateurs de drogues au Togo en 2011. 
22  Enquête de Comportement et de Séroprévalence chez les Militaires 2014 
23  Programme National de Lutte contre le Sida et les IST, 2011. Enquête comportementale et de séroprévalence 
du VIH chez les utilisateurs de drogues au Togo en 2011. 
24  Prudden, H. J., Beattie, T. S., Bobrova, N., Panovska-Griffiths, J., Mukandavire, Z., Gorgens, M., Wilson, D. and 
Watts, C. H. 2015. Factors Associated with Variations in Population HIV Prevalence across West Africa: Findings 
from an Ecological Analysis. PLoS ONE, 10, e0142601. 
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Table 1.2 Population size and prevalence among populations 
POPULATION 
ESTIMATED POPULATION SIZE 
(MOST RECENT VALUE) 
PREVALENCE (MOST RECENT 
VALUE) 
FSW 17,90925,26 11.7% (CI 9.9%-13.5%)27 
FSW Clients 106,847 (estimate)28 1.8% (CI 0.8%-2.6%)29 
MSM 7,64930 13.0 (CI 10.1%-16.0)31 
Drug users 40,80032 5.5% (CI 3.2% – 7.8%)33 
Prisoners 4,34934 4.3% (CI (3.2% – 5.5%)35 
Military 13,80036 3.8% (CI 2.9%-4.7%)37 
 
  
                                                               
25  Papworth E, Grosso A, Ketende S, Wirtz A, Cange C, Kennedy C, Lebreton M, Ky-Zerbo O, Anato S, and Baral S. 
Examining Risk Factors for HIV and Access to Services among Female Sex Workers (FSW) and Men who have 
Sex with Men (MSM) in Burkina Faso, Togo, and Cameroon. March 2014. Baltimore: USAID | Project Search: 
Research to Prevention. The proportion of the population who are FSW in Togo is estimated to be 0.82% (95% 
CI 0.57-1.07%) or 13,771 (95% CI 9,634-17,909).  
26  Conseil National De Lutte Contre Le SIDA, 2015. Etude Sur L’estimation De La Taille Et Cartographie Des Sites 
HSH et PS au Togo. According to these estimates, 6292 (CI 5234-7352) or 2.4%, of the female population 15-49 
living in cities were FSW.  In order to reconcile both these studies, it was decided to use the higher estimate 
from the national study (Papworth et al 2014).   
27  Universite de Lome and Unite de Recherche Demographique. 2015. Enquête comportementale et de 
séroprévalence du VIH chez les professionnelles du sexe et leurs clients au Togo PS-TOGO_2015 
28  Estimate derived from raw data from DHS report. Source: Ministère de la Planification, du Développement et de 
l’Aménagement du Territoire (MPDAT), Ministère de laSanté (MS) et ICF International, 2015. Enquête 
Démographique et de Santé au Togo 2013-2014 . Rockville, Maryland, USA : MPDAT, MS et ICF International. 
29  Universite de Lome and Unite de Recherche Demographique. 2015. Enquête comportementale et de 
séroprévalence du VIH chez les professionnelles du sexe et leurs clients au Togo PS-TOGO 2015 
30  Conseil National De Lutte Contre Le SIDA, 2015. Etude Sur L’estimation De La Taille Et Cartographie Des Sites 
HSH et PS au Togo. 
31  Enquête comportementale et de séroprévalence du VIH chez les hommes ayant des rapports avec d’autres 
hommes (HSH) Togo en 2015 
32  Conseil National De Lutte Contre Le Sida et Les Infections Sexuellement Transmissibles (2014) Rapport De Progres Sur La 
Riposte Au ViIH et Au Sida Au Togo (GARPR 2014)  
33  Programme National de Lutte contre le Sida et les IST, 2011. Enquête comportementale et de séroprévalence 
du VIH chez les utilisateurs de drogues au Togo en 2011. 
34  Direction General de l'Administration Penitenciaire. 
35  Programme National de Lutte contre le Sida et les IST, 2011. Enquête comportementale et de séroprévalence 
du VIH chez les prisonniers Togo en 2011 
36  Expert opinion 
37  Enquête de Comportement et de Séroprévalence chez les Militaires 2014 
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Figure 1.3 Estimated number of new HIV infections transmitted, 2000–14, according to Optima 
modelling 
 
Figure 1.4 Estimated number of new HIV infections acquired, 2000–14, according to Optima 
modelling 
 
An important characteristic of sexual relationships in this context is the frequency of 
transactional sex.  Sex workers in Togo are defined as per the UNAIDS definition, ‘adults 
or youth who receive goods and/or money in exchange for sex’38.  Some sex workers 
define themselves as official sex workers, based in brothels (‘les PS affichees’) and non-
brothel based (‘les PS ambulantes’).  However, a large proportion of sex workers do not 
identify themselves as sex workers (‘les PS clandestines’).  In 2009, 6% of sex workers 
                                                               
38  UNAIDS. Guidance note on HIV and sex work. Geneva, UNAIDS, updated 2012.  
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were brothel-based, 19% were non-brothel based and the majority (75%), did not 
identify themselves as sex workers39.  In this report, the highest available size estimate of 
FSW, 17 909 or 1.07% of the 15-49 female population, was used in order to take as 
much as possible hidden sex workers into account.  
1.3.3 HIV AMONG FEMALES 
The disproportionate burden of HIV among females in Togo is characteristic of the West 
African epidemiological context and most mixed and generalized HIV epidemics.  
Analysis conducted by Prudden et al (2015) highlights the influences of networks 
between older men and young females (Figure 1.3).  In the context of higher prevalence 
among the FSW population, and their clients, an increase in HIV infections has been 
noted when clients and other younger women have sexual relationships, or when either 
of these groups has multiple partners (Figure 1.3).  In Togo, prevalence among young 
females was estimated to be almost five times that of young males in 2013 (2.4% 
compared to 0.5%)40 indicating that young women and older men have sexual 
relationships with one another.  Female youth are also more likely to have multiple 
partners (1.3%) than older females aged 25-49 years (0.4%), and older males aged 25-
49 years are more likely to have multiple partners (22.7%) than male youth (7.5%)41.    
Figure 1.5 Revised conceptual framework of HIV spread through sexual networks of individuals 
within the population42 
 
  
                                                               
39  Pitché, P., Gbetoglo, K., Saka, B., Akakpo, S., Landoh, D.E., d’Alméida, S., Kere, Banla, A.K., Sodji, D., Deku, K. 2013. 
HIV prevalence and behavioral studies in female sex workers in Togo: a decline in the prevalence between 2005 
and 2011. PanAfrican Medical Journal 2013; 15:62. 
40  Evaluation du secteur de l'éducation 2015 
41  Prudden, H. J., Beattie, T. S., Bobrova, N., Panovska-Griffiths, J., Mukandavire, Z., Gorgens, M., Wilson, D. and 
Watts, C. H. 2015. Factors Associated with Variations in Population HIV Prevalence across West Africa: Findings 
from an Ecological Analysis. PLoS ONE, 10, e0142601. 
42  Prudden, H. J., Beattie, T. S., Bobrova, N., Panovska-Griffiths, J., Mukandavire, Z., Gorgens, M., Wilson, D. and 
Watts, C. H. 2015. Factors Associated with Variations in Population HIV Prevalence across West Africa: Findings 
from an Ecological Analysis. PLoS ONE, 10, e0142601. 
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Figure 1.4 Revised conceptual framework of HIV spread through sexual networks of individuals 
within the population (continued) 
 
 
1.3.4 CHARACTERISTICS OF HIV RESPONSE IN TOGO 
A decline in HIV prevalence among males and females aged 15-49 years, between 2000 
and 2014, was previously noted.  This success is attributable in part to the HIV response 
to date.  Self-reported condom use is high for commercial acts with FSW, at 93% in 
2014,43 and 86% with casual partners for MSM in Lomé and Kara in the same year44.   
Of the estimated 110,400 PLHIV in 2014, it is estimated that 52% have been diagnosed45.  
The number of women covered under the Option B/B+46 approach within the PMTCT 
program has increased in recent years.  In 2014, it was estimated that 87% of diagnosed 
pregnant women received treatment47.   
ART coverage has steadily increased since 2000 but remains low at an estimated 33% in 
2014. This is a major challenge, given the individual clinical benefit and population-level 
HIV prevention benefit of treatment.  Togo’s low ART coverage is echoed elsewhere in 
the WCA region, where the ARV treatment gap among those estimated to be eligible for 
treatment according to WHO guidelines is 79%48.  The WCA treatment gap is 13% higher 
                                                               
43  Universite de Lome and Unite de Recherche Demographique. 2015. Enquête comportementale et de 
séroprévalence du VIH chez les professionnelles du sexe et leurs clients au Togo PS-TOGO 2015. 
44  Papworth E, Grosso A, Ketende S, Wirtz A, Cange C, Kennedy C, Lebreton M, Ky-Zerbo O, Anato S, and Baral S. 
Examining Risk Factors for HIV and Access to Services among Female Sex Workers (FSW) and Men who have 
Sex with Men (MSM) in Burkina Faso, Togo, and Cameroon. March 2014. Baltimore: USAID | Project Search: 
Research to Prevention. The proportion of the population that is FSW in Togo is estimated to be 0.82% (95% CI 
CI 0.57-1.07) or 13,771 (95% CI CI 9,634-17,909). 
45  Rapport Annuel D’activite de la Reponse Nationale Contre le VIH/SIDA en 2014. In-country experts 
acknowledge that while this value is the best estimate regarding this indicator, it is still an estimate 
46  Option B, refers to an approach in which “all pregnant and lactating women with HIV initially are offered ART – 
beginning in the antenatal period and continuing throughout the duration of breastfeeding.  At the end of 
breastfeeding those women who do not yet require ART for their own health would discontinue the 
prophylaxis and continue to monitor their CD4 count, eventually re-starting ART when the CD4 falls below 350 
cells/mm3.”.  Option B+ refers to “all pregnant women living with HIV are offered life-long ART, regardless of 
their CD4 count”.  Source: http://www.unicef.org/aids/files/hiv_Key_considerations_options_B.pdf 
47  Togo National HIV Strategic Plan draft 2016-2020. 
48  Based on numbers receiving treatment as of December 2012 and estimated numbers of people eligible as of 
December 2013 under the 2013 WHO HIV treatment guidelines 
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than the global average, and significantly higher than East and Southern Africa where it 
is estimated at 59%49.    
1.4 FINANCING THE HIV RESPONSE IN TOGO 
The HIV response has been heavily dependent on donors’ contribution. HIV spending in 
Togo as percentage of total health expenditure has been decreasing since 2006 (Figure 
1.6). Public spending on HIV as percentage of general government spending on health 
has increased around 50% since 2006, although it has fluctuated substantially during 
this period (Figure 1.6).  
Total HIV spending in Togo increased by nearly 50% between 2006–14 (Figure 1.7).  
During the same period, public funding nearly tripled and international funding has 
increased by approximately 30% (Figure 1.8).  The Global Fund to Fight AIDS, 
Tuberculosis and Malaria (Global Fund) has been the country’s major international 
donor, contributing around 60% of all donor funds in 2014.  
In 2014, the total funding for Togo’s HIV response was approximately USD 21 million, of 
which 75% was financed from international donors and the remainder was funded by 
domestic sources.  In 2014, 12% of domestic funding was financed from private sources.  
Household contributions through out-of-pocket user-fees constituted approximately 
80% of private spending in 2014 (Figure 1.9).  
Figure 1.6 HIV/AIDS spending as a % of total health expenditure and Government expenditure on 
Health Togo50 
   
                                                               
49  UNAIDS 2014, Access to Antiretroviral Therapy in Africa. Status report on progress towards the 2015 targets. 
Geneva, UNAIDS. Source: UNAIDS 2012 estimates. 
http://www.unaids.org/sites/default/files/media_asset/20131219_AccessARTAfricaStatusReportProgressto
wards2015Targets_en_0.pdf 
50  Source: WHO National Health Accounts Database (http://apps.who.int/nha/database/Select/Indicators/en), accessed 
20 April 2016. 
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Figure 1.7 Overall spending on HIV/AIDS in Togo51 
 
Figure 1.8 Funding for HIV in Togo, by funding source52 
 
  
                                                               
51  Source: National HIV/AIDS Spending report 2006-2014. 
52  Source: National HIV/AIDS Spending report 2006-2014 
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Figure 1.9 Private spending on HIV/AIDS in Togo, based on source of funding 53 
 
1.5 A NEED FOR IMPROVING ALLOCATIVE EFFICIENCY 
IN HIV 
In the current climate of increasingly limited resources for HIV epidemic responses, 
focused design and efficiency in service delivery are essential to ensure that programs 
can do more with less.   
A shift towards investment thinking in the design of HIV responses is being promoted by 
the UNAIDS Secretariat and co-sponsors globally, to maximize the impact of program 
investment and best realize the long-term health and economic benefits of HIV 
programs.  Investment cases are currently being developed by a number of countries to 
understand HIV epidemics and design, deliver and sustain effective HIV responses.  In 
support of HIV investment cases, and at the time of drafting Togo’s National HIV 
Strategic Plan 2016–20, this report summarizes the results of an allocative efficiency 
analysis for Togo. 
This report also summarizes the progress made towards reaching key international HIV 
commitments.  In the 2011 UN Political Declaration, countries agreed to reduce sexual 
and injection-related transmission by 50%, virtually eliminate HIV mother-to-child-
transmission, initiate 80% of eligible PLHIV on treatment and end HIV-related 
discrimination by 201554.  The 2014 Gap Report55 illustrated that substantial additional 
effort will be required in most countries to achieve these targets.  Against this 
background, UNAIDS globally defined a Fast-Track56 strategy in order to achieve the 
                                                               
53  Source: National HIV/AIDS Spending report 2006-2014. 
54 United Nations General Assembly (2011) Resolution adopted by the General Assembly 65/277. Political 
Declaration on HIV and AIDS: Intensifying Our Efforts to Eliminate HIV and AIDS. New York. 
55  UNAIDS (2014). The Gap Report. Geneva. 
56  UNAIDS (2014). Fast-track. Ending the AIDS epidemic by 2030. Geneva. 
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goal of Ending AIDS by 2030.  This includes new initiatives such as the 90-90-90 targets57.  
These set out to ensure that 90% of all PLHIV are diagnosed, 90% of diagnosed PLHIV 
are on ART and 90% of PLHIV on ART are virally suppressed.  The Fast-Track approach 
also emphasizes the need to focus on the geographical areas and communities most 
affected by HIV and recommends that resources be concentrated on programs with the 
greatest impact.   
In the context of this report, the investment case is complemented by a human rights-
based approach to health care.  As confirmed in the National HIV Strategic Plan draft 
2016–2058, a universal approach based on upholding human rights and non-
discrimination is to be adopted.   
The concept of allocative efficiency refers to the maximization of health outcomes, with 
the least costly mix of health interventions, within a defined budget envelope.  HIV 
allocative efficiency studies generally try to answer the question “How can a given HIV 
funding amount be optimally allocated to the combination of HIV response interventions 
that will yield the highest impact?”  
There is wide consensus that better outcomes could be achieved in many settings with a 
given amount of HIV funding, or that given outcomes could be achieved with less 
funding, if resources were distributed optimally or if resources were used in the most 
efficient ways.  Mathematical modeling is one way to determine optimized HIV resource 
allocation within defined budget envelopes.  The HIV allocative efficiency (AE) analysis 
in this study was carried out using the Optimization and Analysis Tool (Optima).  The 
results can be utilized to serve the needs of decision-makers and health planners 
seeking to improve the allocative efficiency of their HIV financing. 
 
                                                               
57  UNAIDS (2014). 90-90-90 An ambitious treatment target to help end the AIDS epidemic. Geneva. 
58 Togo National HIV Strategic Plan draft 2016-2020. 
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2 How will this report answer key policy 
questions? 
This report explores whether a different allocation of Togo’s HIV spending could better 
maximize health outcomes and minimize new HIV infections and HIV-related deaths.  
The findings of this report can assist the government of Togo in further strengthening its 
HIV investment case, through which it attempts to increase the effectiveness of HIV 
investments and define corresponding priorities, strategies and impacts of the HIV 
response.  
2.1 THE OPTIMA MODEL 
To assess HIV epidemic trends we use Optima’s epidemic module, which consists of a 
mathematical model of HIV transmission and disease progression.  Optima uses best-
practice HIV epidemic modelling techniques and incorporates evidence on biological 
transmission probabilities, detailed infection progression, sexual mixing patterns and 
drug injection behaviours.  Data relating to programs and costs associated with 
programs are used in an integrated analysis to determine an optimized distribution of 
investment under defined scenarios. Further details of the Optima model are available 
elsewhere (see www.optimamodel.com and Kerr et al59). 
Data from annual reports, bio-behavioral surveys, and clinic registries were 
supplemented with published data and information from national registers to populate 
the Optima Model.  The Optima model was then used to project the likely trajectory of 
the HIV epidemic in Togo and to suggest how that epidemic may best be contained and 
treated with available financial resources. 
Optima is calibrated to HIV prevalence data points available from different sub-
populations (e.g. FSW, MSM, drug users, females 25–49 and males 25–49), at specific 
time points, as well as to data points on the number of people on ART, and data 
surrounding registered HIV/AIDS cases. The calibration process accounted for epidemic 
dynamics, changes in behavioral risk factors and programmatic responses over time, 
and interactions between sub-populations.  Data input and calibration was performed in 
consultation with experts on the Togo epidemic.  Section 2 and Annex 2 provide further 
details regarding the calibration process. 
To assess how incremental changes in spending affect HIV epidemics and thus 
determine the optimized funding allocation, the model parameterizes relationships 
between the cost of HIV intervention programs, the coverage level attained by these 
programs and the resulting outcomes.  These relationships are specific to the country, 
population and program being considered.  
Using the relationships between cost, coverage and outcome—in combination with 
Optima’s epidemic module—it is possible to calculate how incremental changes in 
                                                               
59  Kerr et al, 2015. Optima: A Model for HIV Epidemic Analysis, Program Prioritization, and Resource Optimization. 
JAIDS 2015;69:365-376. http://optimamodel.com/pubs/optima_methods_paper_JAIDS.pdf 
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funding allocated to each program, will impact overall epidemic outcomes.  
Furthermore, by using a mathematical optimization algorithm, Optima is able to 
determine the “optimal” allocation of funding across different HIV programs. 
2.2 ANALYTICAL FRAMEWORK 
To tailor the model to a given context, a number of parameters were selected that 
describe the country population, levels of expenditure, programs to be included or 
excluded, time frames and the baseline scenario.  The parameters appropriate to the 
Togo context are listed in Table 2.1 below. 
Table 2.1 Modeling Parameters 
CATEGORY PARAMETERIZATION IN THE 
OPTIMA MODEL 
DESCRIPTION/ ASSUMPTIONS 
Populations 
defined in the 
model 
1. Female sex workers 
2. Clients of female sex 
workers 
3. Men who have sex with men 
4. Drug users 
5. Prisoners 
6. Military personnel 
7. Children 
8. Male youth 
9. Female youth 
10. Males 25-49 years  
11. Females 25-49 years 
12. Males 50+ 
13. Females 50+ 
 
1. Females, aged 15-49 
2. Males, aged 15+ 
3. Males, aged 15+ 
4. Males, aged 15-49. Refers to all drug 
users, including but not limited to, 
injecting drug users  
5. Males, aged 15-49 
6. Males, aged 15+ 
7. Males and females, aged 0-15 
8. Males, aged 15-24, excluding key 
populations in this age group 
9. Females, aged 15-24, excluding FSW 
10. Males aged 25-49 years excluding 
key populations in this age group 
11. Females aged 25 -49 years excluding 
FSW in this age group 
12. Males aged 50+, excluding key 
populations in this age group 
13. Females aged 50+, excluding key 
populations in this age group 
Program 
expenditure 
areas defined in 
the model and 
included in 
optimization 
analysis 
 
1. Condoms and Social 
Behavior and 
Communication Change 
2.  Programs for female sex 
workers and clients 
3.  Programs for men who 
have sex with men 
4.  Programs for drug users  
5.  Programs for military 
personnel 
6.  HIV testing services 
(general population) 
7. Antiretroviral therapy 
8. HIV prevention programs 
for prisoners 
9. PMTCT 
 
  
1. Condom promotion and distribution. 
Mass media programs, behavior 
change, HIV education  
2.  Service package including 
interpersonal communication and 
counselling, condom provision, peer 
education, HIV testing and 
counselling 
3.  Service package including 
interpersonal communication and 
counselling, condom provision, peer 
education, HIV testing and 
counselling 
4.  Service package including 
interpersonal communication and 
counselling, condom provision, peer 
education, HIV testing and 
counselling  
5.  Service package including 
interpersonal communication and 
counselling, condom provision, peer 
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CATEGORY PARAMETERIZATION IN THE 
OPTIMA MODEL 
DESCRIPTION/ ASSUMPTIONS 
education, HIV testing and 
counselling 
6.  Provider-initiated and voluntary 
testing and counselling (delivered 
outside programs for specific key 
populations) 
7.  Antiretroviral therapy for all 
population groups 
8.  HIV testing and counselling, 
interpersonal communication and 
counselling  
9.  Prevention of mother-to-child 
transmission 
Expenditure 
areas not 
included in 
mathematical 
optimization – 
indirect 
programs 
(because the 
effect on HIV 
incidence, 
morbidity/morta
lity were not 
clear, or because 
the expenditure 
is central 
systems 
expenditure that 
is essential for 
several program 
areas) 
1. Costs for indirect programs, 
also called enablers and 
synergies, have not been 
optimized (as they do not 
have measurable epidemic 
impact) but instead were 
fixed at agreed amounts. 
The components of HIV 
spending that were not 
included in the optimization 
analysis include: 
a. STI 
b. Health infrastructure 
c. HIV care 
d. Management 
e. Human resources and 
training 
f. Enabling environment 
g. Monitoring, evaluation, 
surveillance and 
research 
h. Other 
1. Diagnosis and treatment of sexually 
transmitted infections 
2. Upgrading and construction of 
health infrastructure 
3. Opportunistic infection treatment 
and other care for PLHIV including 
psycho-social support 
4. Co-ordination and response 
management 
5. Cross-cutting human resource costs 
– not specific to individual programs 
6. Advocacy, stigma reduction 
7. Research studies, surveys, 
monitoring evaluation and 
surveillance activities 
8. Includes costs not assigned 
elsewhere such as blood safety, PEP, 
male circumcision, social 
protection, orphans and vulnerable 
children, and other prevention 
programs not classified 
Time frames 
over which the 
optimization was 
considered 
 
 2000 – starting year for data 
entry 
 2016–20 (government’s 
timeline for achievements of 
new national HIV strategic 
plan targets) 
 2020 (interim timeline for 
international targets) 
 2030 (new UNAIDS horizon 
for ending AIDS) 
 
Baseline scenario 
funding 
1. 2014 Global AIDS Response 
Progress Report values 
 
 
2.3 CALIBRATION 
A key stage in the Optima modeling process is a stage known as ‘calibration’.  Calibration 
represents a model validation process in which Optima-projected trends are aligned 
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with the historically observed trends in HIV prevalence in different population groups in 
a given context.  Given the challenges inherent in fitting epidemiological and behavioral 
data, the calibration for Togo was performed manually (i.e. by varying relevant model 
parameters in order to attain a best-fit between model-projected and historic HIV 
prevalence across different population cohorts).  Where data were limited, these trends 
were compared with the registered new diagnoses and Spectrum estimates60.  
Once the Optima model is calibrated, it can project future expected trends in the HIV 
epidemic as described in Section 3. 
2.4 COST-COVERAGE-OUTCOME RELATIONSHIPS 
The relationship between program spending and coverage is shown in the left panel of 
Figure 2.1.  This relationship describes the level of output achieved with a specific level 
of financial input.  In the context of these analyses, output is defined as the availability of 
a service to a specific proportion of the target population.  Coverage refers to the 
number of the population reached.  For example, this relationship would describe how 
many MSM can be provided with a standard package of services with an investment of 0 
to USD 1,000,000.  The relationship between coverage levels and outcome is shown in 
the right panel.  This relationship describes the proportion of people who will adopt a 
specific behavior (such as condom use or consistent use of ARVs leading to viral 
suppression).  These analyses were produced in collaboration with Togo on experts and 
the full set of figures can be seen in the Annex 3.  
The cost-coverage-outcome relationships are utilized, together with the calibration 
projections, to run the optimization and scenario analyses described in Sections 5, 6, 7 
and 8. 
Figure 2.1 Logistic cost-outcome relationships for Togo.61 
 
                                                               
60  http://www.avenirhealth.org/software-spectrum.php 
61  The black dots represent available spending and coverage data, and associated behaviors. The solid curves are 
the best fitting or assumed relationships. 
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2.5 ALLOCATIVE EFFICIENCY ANALYSIS 
Efficiency analyses must be informed by local priorities. Togo is currently drafting a new 
national HIV strategy for 2016–20.  According to the draft National HIV Strategic Plan 
available at the time of this analysis, the strategy for 2016–20 will aim to reduce new 
infections, provide comprehensive care, and ensure good governance62. This is to be 
achieved via a universal approach including targeted prevention, treatment, care and 
support services - all based on upholding human rights and non-discrimination. 
To support these national priorities and assist Togo with sustainability planning, this 
report will answer the following five questions: 1) What is the trajectory of the epidemic 
under different scenarios, in comparison to current epidemic trends under the current 
HIV response? 2) How can Togo optimize the allocation of HIV funding, and how close 
can the country get to minimizing new HIV infections and HIV-related deaths? 3) How 
can Togo optimize the allocation of different levels of HIV funding, and how close will 
the country get to minimizing new HIV infections and HIV-related deaths? 4) What is the 
minimum spend required to achieve National Strategic Plan targets if resources are 
allocated optimally? 5) What are the long-term financial commitments to care and 
treatment for people living with HIV according to different investment options in the 
short-term? 
Each of these questions is the subject of an analytical module as described in more detail 
below. 
ANALYSIS 1: WHAT IS THE TRAJECTORY OF THE EPIDEMIC UNDER DIFFERENT 
SCENARIOS, IN COMPARISON TO CURRENT EPIDEMIC TRENDS UNDER THE 
CURRENT HIV RESPONSE RESOURCE ALLOCATION? 
This analysis compares the trajectory of the epidemic and key outcomes under the 
current allocation of resources described in Section 3, with different scenarios (Section 
5).  These scenarios include: 
1. Attaining 90-90-90 targets: In this scenario it was assumed that by 2020, 90% of 
PLHIV will be aware of their status and 90% of diagnosed PLHIV will be on ART63. 
2. 90% PMTCT coverage: In this scenario, the possible impact of achieving 90% 
PMTCT coverage of all pregnant women living with HIV is explored. 
In the analyses described in Section 5, we estimate the epidemic impact if specific 
outcome levels or targets are achieved, regardless of cost and coverage considerations, 
except for a basic estimate of the cost required to achieve the 90-90-90 targets.  
  
                                                               
62  Togo National HIV Strategic Plan 2016-2020.  
63  Treatment efficacy in reducing new infections for PLHIV on ART was assumed to be 70%.  
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ANALYSIS 2: WHAT CAN BE IMPROVED BY OPTIMIZING THE ALLOCATION OF 
CURRENT FUNDING?  
This analysis compares the trajectory of the epidemic and key outcomes under the 
current allocation of resources, against an optimized allocation of the same resources.  
For the purposes of this analysis, funding remains at current levels and is not varied.  
Only the way that funding is spent changes.  The aim is to determine whether Togo could 
allocate its available resources better.   
 The results of this analysis are described in Section 6. 
ANALYSIS 3: HOW MUCH WILL IT COST TO ACHIEVE PROPOSED NATIONAL HIV 
STRATEGIC PLAN TARGETS?  
This analysis identifies the minimum resource requirements to achieve possible national 
strategy targets.  As the new National HIV Strategic Plan targets had not been fully 
defined at the time of writing, analyses were run to establish how much funding is 
required to a) reduce new infections and deaths by 25% and b) reduce new infections 
and deaths by 50%.  The results of these analyses are presented in Section 7. 
ANALYSIS 4: WHAT ARE THE LONG-TERM FINANCIAL COMMITMENTS TO CARE 
AND TREATMENT OF PEOPLE LIVING WITH HIV ACCORDING TO DIFFERENT 
INVESTMENT OPTIONS IN THE SHORT-TERM? 
This analysis reviews the long-term financial impact of achieving National Strategic Plan 
targets.  Specifically, this analysis compares the commitments one would expect to result 
from the current allocation of the 2014 budget, against the optimized allocation to 
reduce new infections and deaths by 50%, as described in section 7.  The findings from 
this analysis are presented in Section 8. 
2.6 LIMITATIONS OF THE ANALYSIS 
All mathematical models have their strengths and limitations.  Results should therefore 
be interpreted with the necessary caution. However, as with all modeling, this exercise 
used the best data available to produce guidance for decision making as the logical 
implication of available evidence.  In particular, it is important to note that: 
1. All model forecasts are subject to uncertainty. This includes assumptions 
regarding resources available for all programs, including ART and underlying 
behavioral changes.  Therefore, point-estimates are indicative of trends rather 
than exact figures.   
2. The model calibration depends as much on the quality of input data as on the 
quality of the model itself.  The country and study teams have done everything 
possible to ensure the best possible data quality but it is never possible to have a 
complete, or completely certain dataset.  The best model calibration will rarely 
achieve an exact match with historical data, but will closely mirror key trends. 
3. Data in Togo are often not collected specifically for a 25–49 year category, but 
rather for a 15–49 year category, resulting in greater uncertainty around the 
trajectory for 25–49 year olds as there was limited disaggregated data for this 
age-group. 
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4. Surveillance of key populations in this context is complex and may result in the 
underestimation of the size of these populations, as well as an urban bias in the 
estimates. 
5. There is some uncertainty in the epidemic projections for certain populations 
where multiple prevalence data points were available.  These data sometimes 
showed very large decreases in HIV prevalence over a short time frame.  This is 
may be due to a lack of external validity and consistency across survey rounds.  
This was accommodated through the use of ‘best fits’ between observed extreme 
data points. 
6. There is uncertainty surrounding the number of registered PLHIV.  In 2014, it was 
estimated that 57,356 (52%) had been diagnosed64 but this is acknowledged to be 
an estimate as HIV-related deaths are not monitored.  
7. For some population groups, behavioral data (e.g., condom use at last act) and 
population size estimates were limited. 
8. The modeling approach used to calculate relative cost-effectiveness between 
programs includes assumptions about the impact of increases or decreases in 
availability of funding for programs.  These assumptions are based on unit costs 
and observed ecological relationships between outcomes of program coverage or 
risk behavior and the amount of money spent on programs in the past, assuming 
that there would be some saturation in the possible effect of programs with 
increases in spending.  
9. The cost-coverage-outcome relationships were derived from actual cost and 
coverage values for 2014.  As unique identifier codes are not routinely used in 
Togo, coverage estimates were derived using triangulation of available data for 
certain programs and from discussions with country experts.  
10. The analysis presented in this report does not determine the technical efficiency 
of programs as this was beyond the scope of the analysis.  However, gains in 
technical efficiency may lead to lower unit costs and would therefore affect the 
optimized resource allocation described in this report.  
11. Modelling the optimization of allocative efficiencies depends critically on the 
availability of evidence-based parameter estimates of the effectiveness and cost-
efficiency of individual interventions.  Interventions/programs for which these 
parameter estimates do not exist, such as for many of the critical enablers, will be 
excluded for the mathematical optimization analysis.  However, this does not 
mean that these programs should not receive funding. In addition, there are 
uncertainties around parameter estimates of some of the critical clinical 
interventions (e.g., ART and the parameter estimates such as the preventive effect 
of ART), which may distort the results. 
12. Effects of the programs outside the HIV endpoints including, for example, the 
wider health and non-health benefits of FSW and MSM programs (beyond those 
directly related to HIV) and the effects of reduced drug use, are not included in 
this model.   
13. The Optima modeling approach does not seek to quantify the human rights, 
stigma and discrimination, ethical, legal or psychosocial implications of providing 
                                                               
64  Rapport Annuel D’activite de la Reponse Nationale Contre le VIH/SIDA en 2014. In-country experts 
acknowledge that while this value is the best estimate regarding this indicator, it is still an estimate 
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or withdrawing care.  The authors acknowledge that these are important aspects 
to consider when allocating funding to health services. 
14. Other models may produce different projections than those produced by Optima.  
This is an underlying property when using theoretical mathematical frameworks.  
Different designs of the framework may generate different outcome projections.  
In addition, the analyses presented in this report have made use of the best 
available country data, experience gained from applying the Optima model in 
many countries, and comparisons within the WCA region, for the validation and 
contextualization of inputs and findings wherever possible. 
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3 WHAT ARE THE EXPECTED TRENDS IN 
THE EPIDEMIC IF CURRENT SPENDING 
VOLUME AND PATTERNS ARE 
MAINTAINED? 
In this section, the modelled projections of the HIV epidemic are described.  These 
results are based on the calibration process and assume that current (2014) spending 
levels and coverage (absolute number of PLHIV on ART) are maintained.  Further 
calibration results are provided in the Annex 2. 
3.1 PEOPLE LIVING WITH HIV 
With current levels of funding and current allocations to HIV intervention programs 
maintained, the model projects that the number of people living with HIV (PLHIV) is 
projected to increase from a model-estimated 110,400 in 2014, to 117,318  (6%) by 
2020 and 136,447 (24%) by 2030 (Figure 3.1).  This increase is due in part to an 
expected stabilization in HIV incidence and an increase in Togo’s population size65.  
Figure 3.1 shows that in 2014, 60% of PLHIV were females aged 15+ years, whilst males 
aged 15+ years made up 33% of PLHIV. 
Projecting forward to 2030, males are expected to continue to comprise around one-
third of the expected PLHIV, whilst almost two-thirds of PLHIV are expected to be 
female.  The percentage of children living with HIV is expected to reduce over this time 
period.  Amongst both males and females in the general population, the model estimates 
that a larger proportion of PLHIV will be in populations older than 25 years by 2030.  
Key populations made up an estimated 10% of all PLHIV in 2014, and this is expected to 
stabilize at 9% by 2030.  
Figure 3.1 Calibration of PLHIV 
  
 
                                                               
65  https://www.cia.gov/library/publications/the-world-factbook/rankorder/2002rank.html 
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3.2 HIV PREVALENCE  
Overall prevalence is projected to decrease from modeled estimates of 1.6% in 2014 to 
1.5% in 2020 and 1.3% by 2030 (Figure A2.2), although this percentage will be of a 
larger total population in 2030.  Although estimated prevalence is higher among key 
populations than in the general population, the epidemic in most key populations is 
stabilizing.   
Between 2014 and 2030, prevalence is expected to decrease from 16.8% to 13.8% in 
FSW, and as prevalence among clients is substantially influenced by FSW prevalence, 
prevalence among clients is projected to decrease from 2.1% to 1.3%.  Prevalence is also 
projected to decrease among MSM from 16.6% to 13.7%, and from 4.0% to 3.2% among 
prisoners.  Among drug users, prevalence is expected to decline from 5.3% to 4.5% and 
for military personnel, it is expected to decrease from 4.9% to 3.1% over the same time 
period. However, these prevalence estimates should be treated as indicative only.  
Changes in risk behaviors, mobility or interactions with epidemics in neighboring 
countries may influence future trends.  Projections within small populations such as 
these will always be more sensitive to small changes in risk factors than projections 
calculated for larger scale epidemics. 
Among some groups in the general population, prevalence is expected to stabilize, with 
non-significant or very small reductions between 2014 and 2030: from 0.3% to 0.1%, in 
children, from 0.4% to 0.2% among male youths (15–24 years), from 1.3% to 0.8% 
among female youths, from 2.7% to 2.3% in men aged 25–49 years, and from 4.4% to 
3.9% for women of the same age.  Among the general population aged 50+ years, 
prevalence is expected to increase very slightly between 2014 and 2030: from 2.2% to 
2.3% in men and from 3.5% to 4.0% in women in this age category.  This is partially due 
to the positive effects of ART and PLHIV living longer.  
3.3 HIV INCIDENCE 
HIV incidence has declined since 2000 to an estimated 0.09 per 100 person-years in 
2014.  The model predicts that, with the current allocation of funds, overall incidence 
will stabilize from 0.090 in 2014 to 0.097 per 100-person years in 2030.   
New infections are projected to increase by 20% from an estimated 6,300 new infections 
per year in 2014 to 7,500 per year in 2020, and by 57% to an estimated 9800 per year in 
2030 (Figure 3.2).  The majority of new HIV infections in 2014 were estimated to be 
among females 25-49 (45%), males 25–49 (24%) and female youth (14%).  These three 
population groups are predicted to still have the highest number of new infections in 
2030: females 25-49 (46%), males 25–49 (25%) and female youth (11%).   
If PMTCT coverage is not scaled up, the percentage of new infections among children is 
expected to increase from 6% in 2014 to 9% in 2030.  
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Figure 3.2 Calibrated number of new HIV infections per year 
 
3.4 AIDS-RELATED DEATHS ARE LOW BUT PREDICTED 
TO INCREASE 
AIDS-related deaths are estimated to have decreased to approximately 4300 deaths in 
2014.  However, under current coverage of programs, the number of deaths attributable 
to HIV is predicted to increase by 12% to 4,800 in 2020 and by 31% 5,700 (31%) by 
2030 if PLHIV are not diagnosed promptly and put onto treatment66 (Figure 3.3).  
Figure 3.3 Calibration predicted number of deaths due to HIV in Togo67  
  
3.5 THE NUMBER OF PEOPLE REQUIRING HIV 
TREATMENT WILL INCREASE 
At the end of 2014, 33% of PLHIV were receiving HIV treatment.  However, with the 
predicted increase in new infections, demand for treatment will rise and potentially 
widen the substantial existing treatment gap.  Furthermore, Togo currently only 
provides treatment when a CD4 count is less than 500cells/mm3.  However, current 
WHO guidelines now recommend commencing treatment for adults at any CD4 count68.  
If Togo is to adhere to international guidelines for HIV treatment, additional existing 
                                                               
66 Note that in calibration, the Optima model assumes that the number of PLHIV on ART remains constant. 
67  This assumes stable behaviors and coverage of services 
68  WHO, September 2015 (http://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en/) 
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PLHIV will require treatment in additional to a greater proportion of newly diagnosed 
PLHIV. 
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4 WHAT IS THE IMPACT OF PAST AND 
CURRENT SPENDING? 
4.1 TREATMENT RECEIVES THE MAJORITY OF 
CURRENT FUNDING 
Care and treatment including ART and HIV care, is the largest component of HIV 
spending in Togo, at an average of 40% of total spending since 2006 (Figure 4.1).  In 
2014, approximately 50% of total HIV spending was allocated to treatment, most of 
which was spent on ART (Figure 4.1).  As shown in Figure 4.2, the majority of funding 
for treatment in 2014 was financed from international donors.  
By comparison, spending on preventive programs for key and general populations - such 
as condom promotion and social behaviour change communication- constituted around 
15% of total HIV spending in 2014.  Spending on these and other non-ART preventative 
programs has decreased substantially since 2006, when it represented more than 50% 
of HIV spending.  From 2013 to 2014, total spending on key priority prevention and 
treatment programs declined significantly from approximately USD 14 million, to less 
than USD 12 million (Figure 4.3).  In the context of a growing population, this reduction 
signals a significant contraction in per capita spending.  
Program management is the main indirect cost category in this context and constitutes 
an average of 21% of total HIV spending since 2006 (Figure 4.1).  Although spending on 
program management was reduced to 16% of total spending in 2014, this proportion 
remains slightly higher than total spending on preventative programs.  Spending on 
human resource is the second largest indirect cost item, which constituted around 11% 
of total HIV spending in 2014.  Technical efficiency analyses may assist with discerning 
ways in which to decrease these costs.   
Figure 4.1 HIV expenditure in Togo by category69 
 
                                                               
69  Source: National HIV/AIDS Spending report 2006-2014. 
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Figure 4.2 HIV expenditure in Togo by category and funding source for 201470 
 
Figure 4.3 Trends in spending across key priority prevention and treatment programs71. 
 
4.2 CURRENT HIV INVESTMENT AVERTS INFECTIONS 
AND DEATHS 
Model–based projections of the epidemic demonstrate that current spending on HIV 
prevention and treatment programs will continue to avert new infections and deaths.  In 
the absence of any spending on the HIV epidemic, the model estimates that 30,000 
(42%) more deaths would occur and 60,600 (52%) more people would be infected by 
2030 (Figure 4.4).  This highlights the need to continue investing in an HIV response 
and the significant impact of current investments.  
                                                               
70  Source: National HIV/AIDS Spending report 2014. 
71  HTC program mainly covers people from Key Population groups in the context of Togo. 
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Figure 4.4 Model-estimated impact of current spending compared to no spending on the HIV 
response, 2016 – 203072 
 
 
                                                               
72 No spending’ assumes that there is no spending on the HIV response. ‘Current coverage’ assumes that current 
funding levels and allocations remain stable and achieve coverage in line with the cost-coverage-outcome 
curves defined in the model.  
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5 PREDICTING THE TRAJECTORY OF THE 
HIV EPIDEMIC: COMPARING HIV 
RESPONSE SCENARIOS 
5.1 COMPARING HIV RESPONSE SCENARIOS 
In the previous section, we compared current spending levels and allocations, against a 
‘no spending’ scenario.  Figure 4.4 demonstrates that the current response to the 
epidemic is reducing HIV incidence and HIV-related mortality from the levels one would 
expect in the absence of intervention.  The Optima model predicts that this positive 
impact is likely to persist, and even grow, in the time period to 2030.   
In this section, we ask whether reaching pre-specified targets regardless of the budget 
required, could further reduce prevalence, new infections and mortality.  Here we 
compare the trajectory of the HIV epidemic by 2030 under the current HIV response, 
against three alternative response scenarios that are not constrained by a budget but are 
determined solely by targets.  These scenarios were identified through consultation with 
local stakeholders and a range of experts.  The epidemic trajectory is predicted for each 
of these scenarios and compared with the trajectory under current programmes, 
without determining the overall budget envelope required to achieve the defined targets 
in each scenario. 
The two response scenarios used for comparison were:   
1. Attaining 90-90-90 targets: In this scenario it is assumed that by 2020, 90% of 
PLHIV will be aware of their status and 90% of diagnosed PLHIV will be on ART73. 
2. Attaining 90% PMTCT coverage: In this scenario it is assumed that by 2020, 90% 
of all pregnant women living with HIV will be aware of their status, and 90% of 
diagnosed pregnant women living with HIV will be on ART. 
Table 5.1 presents detailed information on parameters and targets specified in the 
alternative scenarios.  
  
                                                               
73  Treatment efficacy in reducing new infections for PLHIV on ART was assumed to be 70%.  
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Table 5.1 Parameters and target values used in the alternative scenarios 
TARGET 
POPULATION 
PARAMETERS ALTERNATIVE RESPONSE 
SCENARIOS* 
  Test and offer 
treatment  
(Baseline-2020) 
Attaining 90% 
PMTCT coverage 
(Baseline – 2020) 
FSWs Proportion of sexual acts in which 
condoms are used with commercial 
partners No change (93%) N/A 
Proportion of people who are tested 
for HIV each year N/A N/A 
Clients of sex 
workers 
Proportion of sexual acts in which 
condoms are used with commercial 
partners No change (61%) N/A 
MSM Proportion of sexual acts in which 
condoms are used with casual 
partners No change (86%) N/A 
Proportion of sexual acts in which 
condoms are used with commercial 
partners No change (67%) N/A 
Proportion of people who are tested 
for HIV each year N/A N/A 
Military Proportion of sexual acts in which 
condoms are used with casual 
partners No change (88%) N/A 
Proportion of sexual acts in which 
condoms are used with commercial 
partners No change (61%) N/A 
Proportion of people who are tested 
for HIV each year N/A N/A 
Drug users Proportion of sexual acts in which 
condoms are used with casual 
partners No change (27%) N/A 
Proportion of people who are tested 
for HIV each year N/A N/A 
Prisoners Proportion of people who are tested 
for HIV each year N/A N/A 
Females  
15–49 
Number of pregnant women 
receiving Option B/B+ N/A 
4496–5913 
(2016–20) 
Number of PLHIV on ART (all populations) 34955-95028 
(2014–20) N/A 
Proportion of people who are tested for HIV in each 
year (all populations) 
52%-90%(2016-
2020) N/A 
Note: * Baseline data in each scenario are from different years when the latest data was available. 
The model-predicted evolution of annual new infections and deaths from 2000 to 2030, 
under these conditions, are shown in Figures 5.1 and 5.2.  For the scenario of attaining 
90% PMTCT coverage (Figure 5.3), expected new infections among children for the 
same period is shown. 
Overall, with the level and allocation of funding and coverage maintained as for 2014, 
the number of new HIV infections and HIV-related deaths are expected to increase. All 
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scenarios significantly reduce the number of new HIV infections and HIV-related deaths 
in comparison with the current spending and allocation.  As previously mentioned 
however, these scenarios are not budget constrained. 
Figure 5.1 Model-predicted evolution of annual new infections comparing current coverage with 
attaining 90-90-90 target (2000–30) 
 
Figure 5.2 Model-predicted evolution of annual HIV-related deaths comparing current coverage 
with attaining 90-90-90 target scenarios (2000–30) 
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Figure 5.3 Model-predicted new infections for children comparing current coverage with attaining 
90% PMTCT coverage 2020 target (2000–30) 
These analyses predict that Scenario 1, attaining 90-90-90 targets, will substantially 
reduce new infections and deaths compared with the current strategy.  Scenario 1 is 
estimated to result in 56% or 63,500 fewer infections, and 68% or 47,900 fewer deaths 
by 2030, compared with current coverage.  
These findings also show that attaining 90% coverage for PMTCT by 2010 (Scenario 2), 
could reduce the number of new infections among children by 35%, with 3,000 new 
infections averted.  
5.2 ESTIMATED BUDGET REQUIRED TO ATTAIN THE 
90-90-90 TARGETS 
In reducing the number of deaths and new infections over time, Scenarios 1 and 2 are 
significantly more effective than the current HIV response.  This demonstrates the 
importance of ensuring high testing and treatment coverage for all populations, 
including key populations.  We now provide estimates for the cost required to attain the 
90-90-90 targets.  In order to derive these estimates, a number of assumptions needed 
to be applied, as noted below: 
 The estimated 110,400 PLHIV in 2014, has been derived from the model 
calibration which takes multiple parameters into account 
 The model assumes that current conditions continue beyond 2014 i.e. stable 
behaviors and coverage of programs 
 2014 unit costs have been applied to all years. For ART this was USD 265.35 per 
patient, per year74 and for testing this was USD 3.91 per test75.  Changes in the unit 
cost over time will affect these estimates.  
                                                               
74 National HIV/AIDS Spending report, 2014. 
75 Coûts unitaires des services de prévention, de traitement et de soutien dans la riposte nationale contre le VIH et 
le Sida au Togo, Aout 2014. 
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 It is assumed that 52% of PLHIV, or 57,356 people, were diagnosed in 201476.  In-
country experts acknowledge that while this value is the best available estimate 
for this parameter, it is remains an estimated figure.  
 It was necessary to make assumptions about the value of the positive testing rate.  
In 2014, 4.9% of the population tested were diagnosed with HIV.  In the first 
instance the value of the positive testing rate was assumed to be stable at 4.9% 
for all years.  Thereafter, the positive testing rate was reduced to 3% and 
increased to 10% in order to explore the resultant budgetary impact. 
 This analysis constitutes a starting point in understanding the costs of reaching 
the 90-90-90 targets. However, this estimate is static and does not include all 
factors that affect the HIV care cascade such as stigma and discrimination. Further 
work is needed in this area. 
5.2.1 COST OF TESTING 
In order to achieve a target of 90% of PLHIV tested and diagnosed by 2020, this would 
cost approximately 3.2 million if 4.9% of the tested population were diagnosed each 
year.  The estimated cost would range between USD 5.3 million (3% positive testing 
rate) and USD 1.6 million (10% positive testing rate).  These are cumulative costs for the 
period 2016–20, at 2014 unit costs, in real terms. 
5.2.2 COST OF TREATMENT 
Achieving a target of 90% of diagnosed PLHIV on treatment by 2020 would cost 
approximately USD 93.7 million for treatment (Table 5.2). These again are cumulative 
costs for the period 2016–20, at 2014 unit costs, in real terms.  This is a conservative 
estimate, assuming a static epidemic and stable unit costs, which would benefit from 
further analysis.  
Table 5.2 Estimated cost required for treatment to reach 90-90-90 target 
YEAR 
ESTIMATED 
NUMBER OF PLHIV 
(OPTIMA 
CALIBRATION 
RESULTS) 
% 
TREATMENT 
COVERAGE 
NUMBER OF 
PLHIV ON 
TREATMENT 
ANNUAL COST TO 
PROVIDE 
TREATMENT IN 
2014 REAL TERMS 
(USD) 
2016 112,313 42.4% 47,621 12,636,057 
2017 113,381 51.8% 58,731 15,584,256 
2018 114,565 61.2% 70,114 18,604,462 
2019 115,876 70.6% 81,808 21,707,660 
2020 117,318 81.0% 95,028 25,215,395 
Total 2016–20    93,747,830 
                                                               
76  Rapport Annuel D’activite de la Reponse Nationale Contre le VIH/SIDA en 2014 
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6 WHAT CAN BE IMPROVED BY 
OPTIMIZING THE ALLOCATION OF 
CURRENT FUNDING? 
An optimization analysis was conducted to compare the allocation of the 2014 budget of 
USD 20,792,57577 with an optimized allocation of the same budget for the time period 
2016–30.   
As figure 21 shows, findings of model-based analyses suggested that Togo is currently 
allocating its HIV budget in an efficient way.  The current distribution of funding differs 
slightly from the model derived optimized allocation of the 2014 budget, which aims to 
minimize both new infections and deaths, but the gains remain too limited to 
significantly impact the course of the epidemic.  
It should be noted however that the model assumes that the indirect cost for 
management and enablers are stable and these were therefore fixed as USD amounts.  
However, if all indirect costs were reduced by 25%, then 16,900 more PLHIV might be 
placed onto treatment.  This could avert approximately 19,900 new infections and 
15,400 deaths by 2030.  As management costs make up a large proportion of indirect 
costs, just reducing management costs by 25% might enable an extra 10,600 people to 
be put onto treatment, thus averting 9,900 deaths and 11,000 new infections by 2030. 
                                                               
77  This figure does not include spending on HIV. However, only direct programs such as key population programs 
(FSW, MSM, drug users, military, prisoner), ART, PMTCT, condoms and SBCC and HTS programs are included in 
the optimization analysis.  The indirect programs or cost items such as management, enabling environment, 
monitoring and evaluation etc. were not included in the optimization analysis. 
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7 HOW MUCH WILL IT COST TO ACHIEVE 
PROPOSED NATIONAL HIV STRATEGIC 
PLAN TARGETS? 
The analysis in this section identifies the minimum annual resource requirements to 
achieve the proposed National Strategy targets described in Section 2.  The analyses in 
this section aim for the full achievement of possible National HIV Strategic Plan targets, 
and determine the minimum investment required to achieve those goals with an 
optimized allocation.  These analyses will assess the funding required to a) reduce new 
infections and deaths by 25% and b) reduce new infections and deaths by 50%. 
Figure 7.1 shows the current allocation of 2014 spending and the minimum spending 
required - with an optimal allocation - to achieve the two targets described above.  The 
model results presented here suggest that 32.2 million USD would need to be invested 
annually to achieve the first target of reducing new infections and deaths by 25%.  This 
includes the fixed indirect costs mentioned previously in Section 6.  This total budget is 
55% more than the 2014 budget of USD 20.8 million.  Similarly, this analysis estimates 
that new infections and deaths could be reduced by 50% with annual spending of 
around USD 39.2 million, which is 88% more than the 2014 spend.  Table 6 shows the 
recommended spend across programs in order to reduce new infections and deaths by 
50%.  
In order to reach proposed targets of reducing new infections and deaths by 50%, the 
model recommends increased investments in ART, PMTCT and non-ART prevention 
programs, especially those targeted at FSW, drug users, prisoner and HTS programs.  
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Figure 7.1 Minimum annual spending required to meet selected targets 
 
Table A1. 1  Current and optimized minimum annual spending required to meet NSP target to 
minimize both new infections an deaths by 50% for the period 2016–13 
PROGRAM 
2014 
SPENDING 
(USD) 
% OF 2014 
BUDGET 
ANNUAL SPEND 
REQUIRED TO 
REDUCE DEATHS 
AND NEW 
INFECTIONS  
BY 50% (USD) 
% OF ANNUAL 
SPEND 
REQUIRED TO 
REDUCE 
DEATHS AND 
NEW 
INFECTIONS BY 
50% 
Condoms & SBCC 1,731,243 8.3% 418,002 1.1% 
DU programs 45,020 0.2% 546,056 1.4% 
Prisoner programs 1,612 0.01% 47,534 0.1% 
HTS 251,929 1.2% 472,589 1.2% 
FSW programs 255,960 1.2% 755,912 1.9% 
MSM programs 77,234 0.4% 3,416 0.01% 
Military programs 4,672 0.02% 3,239 0.01% 
ART 9,275,229 44.6% 25,578,089 65.3% 
PMTCT 624,169 3.0% 2,834,344 7.2% 
MGMT 2,207,263 10.6% 2,207,263 5.6% 
HOW MUCH WILL IT COST TO ACHIEVE PROPOSED NATIONAL HIV STRATEGIC PLAN TARGETS? 
39 
PROGRAM 
2014 
SPENDING 
(USD) 
% OF 2014 
BUDGET 
ANNUAL SPEND 
REQUIRED TO 
REDUCE DEATHS 
AND NEW 
INFECTIONS  
BY 50% (USD) 
% OF ANNUAL 
SPEND 
REQUIRED TO 
REDUCE 
DEATHS AND 
NEW 
INFECTIONS BY 
50% 
HR 2,338,274 11.2% 2,338,274 6.0% 
ENV 277,017 1.3% 277,017 0.7% 
M&E 1,521,866 7.3% 1,521,866 3.9% 
INFR 251,300 1.2% 251,300 0.6% 
STI 69,398 0.3% 70,398 0.2% 
Care 1,441,228 6.9% 1,441,228 3.7% 
Other 419,162 2.0% 419,162 1.1% 
Total 20,792,576  39,185,688  
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8 WHAT ARE THE LONG-TERM FINANCIAL 
COMMITMENTS TO HIV SERVICES FOR 
PLHIV? 
This analysis reviews the long-term financial impact of achieving the National Strategic 
Plan targets.  Long-term impact refers to all long-term financial liabilities arising from 
the commitment to provide HIV and related health services to PLHIV in the future.  In 
monetary terms, a financial commitment is the discounted cost of providing HIV services 
for PLHIV in a particular year.  It includes HIV treatment costs, HIV related health care 
costs and social mitigation costs. 
If the National Strategic Plan targets of reducing incidence and deaths by 50% are met 
by 2020, annual HIV-related response costs will increase by 41% between 2016 and 
2030 due to the expected increase in the number of people on ART and the concomitant 
increase in life expectancy (Figure 8.1). The long-term costs of expanding ART as 
described in these analyses, ignores the income gains from a virally suppressed and 
therefore healthier and more productive working-aged population. The financial 
commitments caused by new infections each year i.e. life-time HIV care costs for newly 
diagnosed cases, could be reduced by 70% between 2016 and 2030 due to the expected 
reduction in new infections (Figure 8.2).  
Figure 8.1 Annual HIV related spending for all old and new HIV infections up to 2030 
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Figure 8.2 Predicted life-time HIV care costs of new diagnosed cases in each year 
 
 
Program management and administration, the main indirect cost category in this 
context, constituted 9% of total HIV spending in 2013.  This is lower than some other 
countries in the region but is higher than HIV care and treatment spending, which 
constituted 7% of total HIV spending in 2013.  Although these indirect costs have been 
fixed in the analyses presented in this report – future work may explore opportunities to 
rationalize program management and administration costs, with the savings then 
allocated to the direct costs of the HIV response. 
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9 CONCLUSION 
The Togolese government has responded effectively to a complex, mixed HIV 
epidemic.  To assess HIV epidemic trends, we used Optima’s epidemic module, 
calibrated to HIV prevalence data points available for different sub-populations in Togo.  
The model was also calibrated to data points on the number of people on ART from 
available data sources and in consultation with Togolese experts.  Analyses using this 
model highlight a strong risk that prevalence and incidence will continue to 
increase overall in Togo, if current ART coverage is not increased.  Togo’s fast 
growing population will continue to challenge the HIV response, even in the context of 
stabilizing prevalence in many sub-populations. 
The analyses suggest that the Togolese government’s opportunities for optimization and 
better allocation of current HIV spending to further minimize HIV incidence, prevalence 
and HIV-related deaths are minimal.  The findings highlight however a significant 
treatment gap, and in this context, argue strongly for additional funding, optimally 
allocated, to achieve 90-90-90 targets and respond most effectively to this epidemic. 
Effective ART scale-up is needed.  Coverage must be increased if global targets are to 
be met:  In 2014, 33% of Togo’s estimated 110,400 people living with HIV received 
treatment, compared with a global target of 81% by 2020.  In order to reduce AIDS-
related death s and new infections, optimizing resource allocations will require 
increased spending on ART.   
In order to reduce the treatment gap, whilst ensuring additional funding for non-ART 
HIV programs for key populations, in particular FSW which are a key driver of the 
epidemic, a series of concomitant actions are required: reduced spending on general 
prevention programs targeting low-risk population, a larger budget envelope, 
prioritization of spending on core programs, reduced spending on indirect programs 
where feasible, technical efficiency gains, investment from budgets not earmarked for 
HIV that benefit from the broader public health impacts of key population programs.  
The analysis shows indeed that in order to reduce incidence and deaths by 50%, 
resources should be shifted from prevention programs targeting the general low risk 
population to non-ART key population programs, ART and PMTCT.  
Key population HIV programs would benefit from fully integrating ART initiation 
and adherence.  As ART is an effective prevention strategy, it would be beneficial if ART 
was a central component of the prevention strategy and as such, integrated into the 
design and implementation of prevention strategies.  The model recommends a 
proportionately higher increase of spending of key populations within PLHIV to be put 
onto treatment.  
Additional domestic resources will be needed to sustain the HIV response.  
Funding for HIV in Togo has increased since 2007.  However, excluding ART, preventive 
programs and programs targeted at key populations are primarily funded by 
international donors.  As such, the withdrawal of international funding without a 
concurrent increase in domestic resources would have a significant negative impact on 
the HIV epidemic in Togo.   
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Greater technical efficiency in spending might be achieved through strategies to 
reduce the average spend per person reached.  This is particularly true for indirect 
spending.  Care should be taken however, that these strategies do not compromise the 
quality of prevention or treatment and further analyses of technical efficiency are 
needed before more robust conclusions can be reached. 
By modelling the likely trajectories of the HIV epidemic under different conditions, the 
analysis highlighted the significant gains already achieved with current spending in the 
form of new infections and deaths averted.  However, analyses of what may be 
needed to achieve the proposed targets of the National Strategic Plan have 
identified a clear need for increased investment in an optimized HIV response in 
Togo. All the results from this study point towards the conclusion that Togo 
currently doesn’t have the appropriate resources to achieve its targets and that 
optimization gains alone cannot close this gap.  
 45 
10 ANNEXES 
ANNEX1 OPTIMA MODEL: TECHNICAL 
SUMMARY 
This Annex provides a brief technical overview of Optima. A more detailed summary of 
the model and methods is provided elsewhere.1 Optima is based on a dynamic, 
population-based HIV model. Schematic A, within Figure A1.1A provides an example of 
some of the populations included in the model and mixing patterns used in Optima. 
Schematic B, within Figure A1.1B shows the disease progression implemented in the 
model. Optima tracks the entire population of people living with HIV (PLHIV) across 5 
stages of CD4 count. These CD4 count stages are aligned to the progression of WHO 
treatment guidelines, namely, acute HIV infection, >500, 350–500, 200–350, 50–200, 
and, 50 cells per microliter. Key aspects of the antiretroviral therapy (ART) service 
delivery cascade are included: from infection to diagnosis, ART initiation on first-line 
therapy, treatment failure, subsequent lines of therapy, and HIV/AIDS-related or other 
death.  
Figure A1.1A Example population groups and HIV transmission-related interactions in Optima.  
 
  
                                                               
1  Kerr C, Stuart R, Gray R, Shattock A, Fraser N, Benedikt C, Haacker M, Berdnikov M, Mahmood AM, Jaber SA, 
Gorgens M, Wilson DP. Optima: a model for HIV epidemic analysis, program prioritization, and resource 
optimization. In: JAIDS Journal of Acquired Immune Deficiency Syndromes 03/2015. 
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Figure A1.1B Schematic diagram of the health state structure of the model 
 
Note: Each compartment represents a single population group with the specified health state while each arrow 
represents the movement of numbers of individuals between health states. All compartments except for 
“susceptible” represent individuals living with HIV. Death includes all causes of death. 
The model uses a linked system of ordinary differential equations to track the 
movement of PLHIV between HIV health states; the full set of equations is provided in 
the supplementary material to a summary paper on the Optima model. The overall 
population is partitioned in 2 ways: by population group and by HIV health state. 
Individuals are assigned to a given population group based on their dominant risk.2 HIV 
infections occur through the interaction between different populations by regular, 
casual, or commercial (including transactional) sexual partnerships, through sharing of 
injecting equipment or through mother-to-child transmission. The force-of-infection is 
the rate at which uninfected individuals become infected, and it depends on the number 
and type of risk events to which individuals are exposed in a given period (either within 
their population groups or through interaction with other population groups) and the 
infection probability of each event. Mathematically, the force of- infection has the 
general form: 
; 
where λ is the force-of-infection, β is the transmission probability of each event, and n is 
the effective number of at-risk events (ie, n gives the average number of interaction 
events with HIV-infected people where HIV transmission may occur). The value of the 
transmission probability βvaries across CD4 count compartments (indirectly reflecting 
the high viral load at early and late stages of infection), differs for different modes of 
transmission (intravenous drug injection with a contaminated needle–syringe, penile–
vaginal or penile–anal intercourse, and mother-to-child), and maybe reduced by 
                                                               
2 However, to capture important cross-modal types of transmission, relevant behavioral parameters can be set to 
non-zero values (eg, males who inject drugs may engage in commercial sex; some MSM may have female sexual 
partners). 
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behavioral interventions (e.g., condom use), biological interventions (e.g., male 
circumcision), or ART. 
There is one force-of-infection term for each type of interaction [e.g., casual sexual 
relationships between male sex workers and female sex workers (FSW)]; the force-of-
infection for a given population will be the sum of all interaction types.3 In addition to 
the force-of-infection rate, which is the number of individuals who become infected with 
HIV per year, there are 7 other ways individuals may change health states.4  
The change in the number of people in each compartment is determined by the sum over 
the relevant rates described above, multiplied by the population size of the 
compartments on which they act. 5 
                                                               
3 For sexual transmission, the force-of-infection is determined by:  
• The HIV prevalence (weighted by viral load) in partner populations;  
• The average number of casual, regular, and commercial homosexual and heterosexual acts per person per year; 
• The proportion of these acts in which condoms are used;  
• The proportion of men who are circumcised;  
• The prevalence of sexually transmissible infections (which can increase HIV transmission probability);  
• The proportion of acts that are covered by pre-exposure prophylaxis and post-exposure prophylaxis; 
• The proportion of partners on antiretroviral treatment (ART); and  
• The efficacies of condoms, male circumcision, post-exposure prophylaxis, pre-exposure prophylaxis, and ART at 
preventing HIV transmission.  
For injecting-related transmission, the force-of-infection 
is determined by: 
• The HIV prevalence (weighted by viral load) in populations 
• of people who use a syringe and then share it; 
• The number of injections per person per year; 
• The proportion of injections that use shared equipment; 
• The fraction of people who inject drugs on opioid substitution therapy and its efficacy in reducing injecting 
behavior. 
For mother-to-child transmission, the number of-infections is determined by: 
• The birth rate among women living with HIV; 
• The proportion of women with HIV who breastfeed; 
• The probability of perinatal HIV transmission in the 
• absence of intervention; and 
• The proportion of women receiving prevention of mother-to- child transmission (PMTCT), including ART. 
4  First, individuals may die, either because of an average background death rate for that population (which is 
greater for older populations or for people who inject drugs) or because of HIV/AIDS (which depends on CD4 
count). Second, in the absence of treatment, individuals progress from higher to lower CD4 counts. Third, 
individuals can move from undiagnosed to diagnosed states based on their HIV testing rate, which depends on 
CD4 count (eg, people with AIDS symptoms or primary HIV infection may have a higher testing rate) and 
population type (eg, FSW may test more frequently than males in the general population). Fourth, diagnosed 
individuals may commence ART, at a rate depending on CD4 count. Fifth, individuals may experience treatment 
failure because of lack of adherence to therapy or development of drug resistance, and sixth, people may initiate 
second and subsequent lines of treatment from treatment failure. Finally, while on successful first- or second-
line treatment (ie, effective viral suppressive therapy), individuals may progress from lower to higher CD4 
counts. 
5 For example, the change in the number of undiagnosed HIV-positive FSW with a CD4 count between 200 and 
350 cells per microliter is:  
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Table A1.1 Input parameters of the model 
 
Each compartment (B, boxes) corresponds to a single differential equation in the model, 
and each rate (Fig. A1.1B, arrows) corresponds to a single term in that equation. Table 
A1.1 lists the parameters used in Optima; most of these are for calculating the force-of-
infection. We interpret empirical estimates for model parameter values in Bayesian 
terms as previous distributions. The model must then be calibrated, which is the process 
of finding posterior distributions of the model parameter values such that the model 
generates accurate estimates of HIV prevalence, the number of people on treatment, and 
any other epidemiological data that are available (e.g., HIV-related deaths). The 
calibration can be performed automatically, manually, or a combination of both. This 
process of model calibration and validation should normally be performed in 
consultation with governments in the countries in which the model is being applied. 
HIV RESOURCE OPTIMIZATION AND PROGRAM COVERAGE 
TARGETS 
A novel component of Optima is its ability to calculate allocations of resources that 
optimally address one or more HIV-related objectives (e.g., impact-level targets in a 
country’s HIV national strategic plan). Because Optima also calculates the coverage 
levels required to achieve these targets, it can be used to inform HIV strategic planning 
and the determination of program coverage levels. The key assumptions of resource 
optimization are the relationships between (1) the cost of HIV programs for specific 
                                                                                                                                                                           
 
 where UFSW2002350 is the current number of undiagnosed HIV-positive FSW with a CD4 count between 200 and 
350 cells per microliter, UFSW3502500 is the same population but with higher CD4 count (350–500 cells/mL), t is 
the disease progression rate for the given CD4 count (where 1/t is the average time to lose 150 CD4 cells/mL), 
m is the death rate, and h is the HIV testing rate. (Note: this example does not consider movement between 
populations, such as FSW returning to the general female population and vice versa— something which is also 
included in Optima.)  
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target populations, (2) the resulting coverage levels of targeted populations with these 
HIV programs, and (3) how these coverage levels of HIV programs for targeted 
populations influence behavioral and clinical outcomes. Such relationships are required 
to understand how incremental changes in spending (marginal costs) affect HIV 
epidemics.6 Logistic functions can incorporate initial start-up costs and allow changes in 
behavior to saturate at high spending levels, thus better reflecting program reality. The 
logistic function has the form: 
 
where L(x) relates spending to coverage, x is the amount of funding for the program, A is 
the lower asymptote value (adjusted to match the value of L when there is no spending 
on a program), B is the upper asymptote value (for very high spending), C is the 
midpoint, and D is the steepness of the transition from A to B. For our fits, we typically 
choose saturation values of the coverage to match behavioral data in countries with 
heavily funded HIV responses.7 To perform the optimization, Optima uses a global 
parameter search algorithm called Bayesian adaptive locally linear stochastic descent 
(BALLSD). BALLSD is similar to simulated annealing in that it makes stochastic downhill 
steps in parameter space from an initial starting point. However, unlike simulated 
annealing, BALLSD chooses future step sizes and directions based on the outcome of 
previous steps. For certain classes of optimization problems, we have shown that 
BALLSD can determine optimal solutions with fewer function evaluations than 
traditional optimization methods, including gradient descent and simulated annealing. 
  
                                                               
6 A traditional approach is to apply unit cost values to inform a linear relationship between money spent and 
coverage attained. This is a reasonable assumption for programs like an established ART program that no 
longer incurs start-up or initiation costs, but less appropriate for condom promotion and behavior change 
communication programs. Most HIV programs typically have initial setup costs, followed by a more effective 
scale-up with increased funding. However, there are saturation effects for very high coverage levels because 
these require increased incremental costs because of demand generation and related activities for the most 
difficult-to-reach groups. Optima uses a logistic function fitted to available input data to model cost–coverage 
curves (See Annex 3). 
7  Program coverage for zero spending, or behavioral outcomes for zero coverage of formal programs, is inferred 
using data from early on in the epidemic or just before significant investment in HIV programs. Practically, we 
also discussed the zero and high spending cases with local experts who can advise on private sector HIV service 
delivery outside the governments’ expenditure tracking systems. For each HIV program, we derive one set of 
logistic curves that relate funding to program coverage levels and another set of curves (generally linear 
relationships) between coverage levels and clinical or behavioral outcomes (ie, the impacts that HIV strategies 
aim to achieve). 
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UNCERTAINTY ANALYSES 
Optima uses a Markov chain Monte Carlo (MCMC) algorithm for performing automatic 
calibration and for computing uncertainties in the model fit to epidemiological data. 
With this algorithm, the model is run many (typically 1000–10,000) times to generate a 
range of epidemic projections; their differences represent uncertainty in the expected 
epidemiological trajectories. The most important assumptions in the optimization 
analysis are associated with the cost–coverage and coverage– outcome curves. To 
incorporate uncertainty in these curves, users define upper and lower limits for both 
coverage and behavior for no spending and for very high spending.8 
                                                               
8  All available historical spending data and achieved outcomes of spending, data from comparable settings, 
experience, and extensive discussion with stakeholders in the country of application can be used to inform 
these ranges. All logistic curves within these ranges are then allowable and are incorporated into uncertainty 
analyses of Optima. These cost–coverage and coverage–outcome curves are thus reconciled with the 
epidemiological, behavioral, and biological data in a Bayesian optimal way, thereby allowing the calculation of 
unified uncertainty estimates. 
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ANNEX 2 CALIBRATION FIGURES 
Figure A2.1 Calibration of HIV prevalence among key populations and the overall HIV prevalence1 
  
 
 
 
 
 
 
 
 
 
 
 
                                                                
1 Black dots represent available data for the number of people on ART. Lines attached to these discs represent uncertainty 
bounds. The solid curve is the best fitting simulation of total ART patient numbers. 
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Figure A2.1  Calibration of HIV prevalence among key populations and the overall HIV prevalence2 
(continued) 
 
 
 
 
 
 
 
 
 
 
In the calibration process, model parameters were varied in order to obtain the most 
accurate fit from the available data for FSW, clients, MSM, drug users, prisoners, military 
personnel, male youth, female youth, females 25–49 and males 25–49 populations.  Data 
for children, males 50+ and females 50+ populations were very limited and therefore 
the model was not calibrated against them but instead, model-derived estimates were 
utilized.  In the case of fitting the prevalence in FSW, clients, MSM and male and female 
youth, there were large spreads in the historic data.  Therefore, average estimates were 
used to derive the fitted curves (Figure A2.2).  
  
                                                               
2 Black dots represent available data for the number of people on ART. Lines attached to these discs represent uncertainty 
bounds. The solid curve is the best fitting simulation of total ART patient numbers. 
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Figure A2.2 Model calibration to overall Incidence of HIV 
 
Figure A2.3 Model calibration of number of DALYs  
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Figure A2.4 Model calibration of number of HIV diagnoses 
 
Figure A2.5 Model calibration of number on treatment overall  
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ANNEX 3 COST-COVERAGE OUTCOME 
CURVES 
Table A3.1 Selected behaviors affected by HIV programs 
HIV Program 
 Targeted Behavior (correlating parameter in 
model) 
Programs for female sex workers and 
clients (package) 
 Proportion of sexual acts in which condoms 
are used with commercial partners (FSW) 
 Proportion of FSW who are tested for HIV 
each year  
Programs for men who have sex with men 
(package) 
 Proportion of sexual acts in which condoms 
are used with casual partners (MSM) 
 Proportion of MSM who are tested for HIV 
each year 
Programs for military personnel (package)  Proportion of sexual acts in which condoms 
are used with casual partners  
 Proportion of military personnel who are 
tested for HIV each year 
Programs for drug users (package)  Proportion of sexual acts in which condoms 
are used with casual partners (drug users) 
 Proportion of drug users who are tested for 
HIV each year 
Programs for prisoners (package)  Proportion of people tested for HIV each year 
(prisoners) 
PMTCT  Number of HIV positive pregnant mothers 
receiving Option B/B+  (all selected 
populations) 
Condom promotion and distribution and 
Social Behavior Change Communication 
(SBCC) (package) 
 Proportion of sexual acts in which condoms 
are used with casual partners (male youth) 
 Proportion of sexual acts in which condoms 
are used with casual partners (female youth) 
 Proportion of sexual acts in which condoms 
are used with casual partners (males 25-49) 
 Proportion of sexual acts in which condoms 
are used with casual partners (females 25-49) 
HIV testing and counseling (general 
population) 
 Proportion of male youth who are tested for 
HIV each year 
 Proportion of female youth) who are tested 
for HIV each year 
 Proportion of males 25-49 who are tested for 
HIV each year 
 Proportion of females 25-49 who are tested 
for HIV each year 
 Proportion of males 50+) who are tested for 
HIV each year 
 Proportion of females 50+ who are tested for 
HIV each year 
Antiretroviral therapy  Number of people on ART (all population 
groups) 
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COST-COVERAGE OUTCOME CURVES FOR FSW PROGRAMS  
Figure A3. 1 FSW – number covered by sex worker programs each year 
 
Figure A3. 2 FSW – proportion of people who are tested for HIV each year 
 
Figure A3. 3 FSW - Proportion of sexual acts in which condoms are used with commercial partners 
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COST-COVERAGE OUTCOME CURVES FOR MSM PROGRAMS  
Figure A3. 4 MSM – number of people covered by the MSM programs 
  
Figure A3. 5 MSM – proportion of sexual acts in which condoms are used with casual partners 
  
Figure A3. 6 MSM – proportion of people tested for HIV each year 
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COST-COVERAGE OUTCOME CURVES FOR MILITARY 
PERSONNEL PROGRAMS  
Figure A3. 7 Military personnel  – number of people covered by the military programs 
 
Figure A3. 8 Military personnel – proportion of sexual acts in which condoms are used with casual 
partners 
  
Figure A3. 9 Military personnel – proportion of people tested for HIV each year 
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COST-COVERAGE OUTCOME CURVE FOR PMTCT PROGRAMS 
Figure A3. 10 PMTCT therapy – number of people covered 
 
COST-COVERAGE OUTCOME CURVE FOR DRUG USERS 
PROGRAMS 
Figure A3. 11 Drug users – proportion of people covered by drug user programs 
 
Figure A3. 12 Drug users – proportion of sexual acts in which condoms are used with casual 
partners 
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Figure A3. 13 Drug users – proportion of people who are tested for HIV each year 
 
COST-COVERAGE OUTCOME CURVES FOR PRISONERS 
PROGRAMS  
Figure A3. 14 Prisoners – proportion of people covered by prisoner programs 
 
Figure A3. 15 Prisoners– proportion of people who are tested for HIV each year 
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COST-COVERAGE OUTCOME CURVES FOR GENERAL 
POPULATION MALE AND FEMALE POPULATION GROUPS  
Figure A3. 16 General population – proportion of sexual acts in which condoms have been used with 
casual partners 
 
Figure A3. 17 Male youth population – proportion of sexual acts in which condoms have been used 
with casual partners 
  
Figure A3. 18 Female youth population – proportion of sexual acts in which condoms have been 
used with casual partners 
 
  
OPTIMIZING INVESTMENTS FOR A SUSTAINABLE AND EFFICIENT HIV RESPONSE IN TOGO 
62 
Figure A3. 19 Males 25-49 population – proportion of sexual acts in which condoms have been used 
with casual partners 
 
Figure A3. 20 Females 25-49 population – proportion of sexual acts in which condoms have been 
used with casual partners 
 
Figure A3. 21 General population – proportion of people tested for HIV 
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Figure A3. 22 Male youth population – proportion of people tested 
 
Figure A3. 23 Female youth population – proportion of people tested 
 
Figure A3. 24 Males 25-49 population – proportion of people tested 
 
Figure A3. 25 Female 25-49 population – proportion of people tested 
 
 
OPTIMIZING INVESTMENTS FOR A SUSTAINABLE AND EFFICIENT HIV RESPONSE IN TOGO 
64 
Figure A3. 26 Males 50+ population – proportion of people tested 
 
Figure A3. 27 Females 50+ population – proportion of people tested 
 
COST-COVERAGE OUTCOME CURVE FOR ART 
Figure A3. 28 Antiretroviral therapy – number of people covered (all population groups) 
 
 
 ANNEX 4 DATA TABLES  
  Population size (Thousands) 
POPULATION SIZE (THOUSANDS)  
  2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 
Best 12.4 12.8 13.2 13.6 14.1 14.5 14.9 15.3 15.8 16.2 16.7 17.1 17.6 17.9 18.6 
FSW Clients Best 67.6 69.8 72.2 74.7 77.2 79.9 82.5 85.2 88.1 91.0 94.0 97.1 100.2 103.5 106.8 
Best 7.6 7.6 7.6 7.6 7.6 7.6 7.6 7.6 7.6 7.6 7.6 7.6 7.6 7.6 7.6 
Drug Users Best 40.8 40.8 40.8 40.8 40.8 40.8 40.8 40.8 40.8 40.8 61 59 59 59 40.8 
 Best 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 4.1 4.3 4.1 4.3 4.3 
Best 13.8 13.8 13.8 13.8 13.8 13.8 13.8 13.8 13.8 13.8 13.8 13.8 13.8 13.8 13.8 
Best 216.1 220.8 225.7 230.7 235.8 241.2 247.5 253.0 260.3 267 273 280.9 288 295 301.9 
Male Youth Best 46 47.5 49.1 50.6 52.1 52.6 54.8 56 57.2 58.4 58.6 59.8 61.0 62.3 64.6 
Female Youth Best 50.8 52.2 53.7 55.1 56.5 57.9 59.0 60.2 61.4 62.6 63.8 64.9 66.1 67.3 68.7 
-49) Best 509.6 529.8 551.5 574.7 599.2 615.4 650.7 678.0 706.5 735.9 755.5 787.2 819.164 851.7 894 
Females (25-49) Best 641.3 663.4 686.6 710.9 736.2 762.6 788.8 816.2 844.5 873.8 903.9 934.2 965.7 998.1 1030.1 
 Best 200.6 205.1 209.7 214.6 219.7 225 230.2 235.8 241.7 247.9 254.4 261.6 269.4 277.6 286.4 
Females 50+ Best 248.2 253.8 259.6 265.8 272.3 279.2 285.9 293.2 300.9 309.1 317.8 327.4 337.6 348.6 360.2 
  HIV prevalence (percentage) 
HIV PREVALENCE (PERCENTAGE) 
  2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014  Assumption
High            15.1   13.5 OR 
Best      29.5      13.1   11.7 OR 
Low            11.1   9.89 OR 
FSW Clients 
High            3.6   2.6 OR 
Best            2.5   1.8 OR 
Low            1.4   0.8 OR 
High            23.8   16.3 OR 
Best            19.6   13 OR 
Low            15.9   10.1 OR 
Drug Users 
High                OR 
Best            5.5    OR 
Low                OR 
 
High                OR 
Best            4.3    OR 
Low                OR 
High      16       11.3      9.3          4.7 OR   
Best      13.78        9.7     7.7          3.8 OR  
Low      12        7.7     6.1          2.9 OR   
 
  HIV prevalence (percentage) (continued) 
HIV PREVALENCE (PERCENTAGE) 
 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014  Assumption
High                OR 
Best                OR 0.4
Low                OR 
Male Youth High                OR 
Best             0.6 0.5 0.3 OR 
Low                OR 
Female Youth High                OR 
Best       3.38      2.4 2.4 0.8 OR 
Low                OR 
High                OR 
Best               2.65 OR 
Low                OR 
Females (25-49) High                OR 
Best               4.34 OR 
Low                OR 
Males (50+) High                OR 
Best                OR 0.84
Low                OR 
 
  HIV prevalence (percentage) (continued) 
HIV PREVALENCE (PERCENTAGE) 
 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014  Assumption
Females (50+) High                OR 
Best                OR 4.40
Low                OR 
  Testing and treatment   
TESTING AND TREATMENT 
 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 Assumption
FSW 0.88 
           
8.8 11.3 48.2 OR 
FSW Clients 0.43 
           
4.3 3.7 3.1 OR 
MSM 0.59 
           
5.9 4.7 8.0 OR 
Drug Users 0.02 
           
0.2 0.5 0.6 OR 
Prisoners 0.7 
           
7.0 18.7 18.4 OR 
Military 1.68 
           
16.8 16.8 16.8 OR 
Children 0.04 
           
0.4 0.4 0.3 OR 
Male Youth 0.34            3.4 3.3 2.2  
Female Youth 1.36            13.6 14.6 13.4  
Males (25-49) 0.69            6.9 5.9 5.0  
Females (25-49) 1.29            12.9 12.6 12.3  
Males (50+) 0.2            2.0 1.5 1.4  
Females (50+) 0.13            1.3 1.1 1.0  
 
   Testing and treatment (continued) 
TESTING AND TREATMENT 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 
 
Assumption
Probability of a person being 
tested with CD4 <200  per 40 
             
80 OR 
No. on treatment 0 0 35 142 1002 1,961 4,865 4,419 8,653 11,571 17,664 25,413 28,737 30,666 34,955 OR 
Treatment eligibility criterion 200 200 200 200 200 200 200 200 200 200 350 350 350 350 350 OR 
Percentage 
covered by 
exposure 
prophylaxis 
FSW                OR 0
FSW Clients                OR 0
MSM                OR 0
Drug Users                OR 0
Prisoners                OR 0
Military                OR 0
Children                OR 0
Male Youth                OR 0
Female Youth                OR 0
Males (25-49)                OR 0
Females (25-49)                OR 0
Males (50+)                Or 0
Females (50+)                OR 0
No. women on PMTCT (Option B/B+) 720 910 1,036 1,699 1,986 3,126 4,173 4,411 4,478 4,496 OR 
 
   Testing and treatment (continued) 
TESTING AND TREATMENT 
 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 
 
Assumption
(births per 
woman per 
FSW 0.17 0.17 0.17 0.17 0.17 0.16 0.16 0.16 0.16 0.16 0.16 0.15 0.15 0.15 
 
OR 
Female Youth 
0.17 0.17 0.17 0.17 0.17 0.16 0.16 0.16 0.16 0.16 0.16 0.15 0.15 0.15 0.17 OR 
Females 25-49 0.14 0.14 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.15 0.15 0.15  OR 
Females 50+                OR 0
positive women who breastfeed          87 79 69 77 83 89 93 94 96  OR  
 Optional indicators 
OPTIONAL INDICATORS 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 
Number of HIV tests per year 
     
44,005 82,006 88,938 99,541 133,989 206,173 267,173 309,736 310,189 296,959
Number of HIV diagnoses per 
     
5,281 8,201 9,621 9,904 7,669 13,994 11,364 17,775 15,634 14,610
Modeled estimate of new HIV 
infections per year 13,096 12,315 11,667 10,892 10,151 9,620 9,109 8,707 8,101 7,552 6,925 5,440 4.995 4,712 4,401
Modeled estimate of HIV 
ce 
3.48 3.54 3.55 3.51 3.44 3.35 3.26 3.15 3.20 2.89 2.78 2.68 2.59 2.5 
Number of HIV-related 
5,052 5,680 6,277 6,753 6,958 7,046 6,640 6,988 7,330 7,051 6,279 4,943 4,386 4,137 4,346
Number of people initiating 
ART per year 
            6,999 6,586 7,230
  Sexual acts per person per year 
SEXUAL ACTS PER PERSON PER YEAR 
  2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 
 
Assumption
number of 
sexual acts 
FSW                OR 31.0 
FSW Clients                OR 32.0 
MSM                OR 41.0 
Drug Users            35.1    OR  
Prisoners                OR 0.0 
Military   38.7 29.5  71.6          OR  
Children                OR 0.0 
Male Youth               3.0 OR  
Female Youth               12.0 OR  
Males (25-49)               32.0 OR  
Females (25-
49) 
              28.0 OR  
Males (50+)               32.0 OR  
Females (50+)               22.0 OR  
 Table A7: Sexual acts per person per year (Cont.) 
SEXUAL ACTS PER PERSON PER YEAR 
  2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 
 
Assumption
number of 
FSW                OR 7.0 
FSW Clients                OR 7.0 
MSM       19.2    21.2     OR  
Drug Users            20.8    OR  
Prisoners            0.6    OR  
Military   4.3 4.1  4.8    22.4      OR  
Children                OR 0.0 
Male Youth               16.0 OR  
Female Youth               5.0 OR  
Males (25-49)               7.0 OR  
Females (25-
49) 
              7.0 OR  
Males (50+)               2.0 OR  
Females (50+)               6.0 OR  
 
 Table A7: Sexual acts per person per year (continued) 
ACTS PER PERSON PER YEAR 
  2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 
 
Assumption
number of 
commercial 
FSW            1924.0   2134.1 OR  
FSW Clients      15.7      23.5   27.7 OR  
MSM               59.0 OR  
Drug Users                OR 0.0 
Prisoners                OR 0.0 
Military                OR 0.2 
Children                OR 0.0 
Male Youth                OR 0.0 
Female Youth                OR 0.0 
Males (25-49)                OR 0.0 
Females (25-49)                OR 0.0 
Males (50+)                OR 0.0 
Females (50+)                OR 0.0 
 
  Condom use, and circumcision probability 
CONDOM USE, AND CIRCUMCISION PROBABILITY 
  2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 
 
Assumption
Condom use 
% for regular 
FSW                OR 3 
FSW Clients                OR 6 
MSM          44 69 56   71 OR  
Drug Users            27    OR  
Prisoners                OR  
Military   41 68  80     68     OR  
Children                OR 0 
Male Youth               8 OR  
Female Youth               6 OR  
Males (25-49)               6 OR  
Females (25-49)               3 OR  
Males (50+)               3 OR  
Females (50+)               2 OR  
Condom use 
% for casual 
FSW               40 OR  
FSW Clients            61    OR  
MSM          38 69 56   86 OR  
Drug Users            27    OR  
Prisoners            0    OR  
 
 Table A4.6 Condom use, and circumcision probability (continued) 
CONDOM USE, AND CIRCUMCISION PROBABILITY 
 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 
 
Assumption
Military   84 94  99 75  52  88     OR  
Children                OR  
Male Youth              63 57 OR  
Female Youth              59 51 OR  
Males (25-49)            50   65 OR  
Females (25-49)            29   30 OR  
Males (50+)               29 OR  
Females (50+)               13 OR  
Condom use 
commercial 
FSW          90  91   93 OR  
FSW Clients    12  7         61 OR  
MSM           67     OR  
Drug Users                OR  
Prisoners                OR  
Military                OR 61 
Children                OR  
Male Youth                OR  
Female Youth                OR  
Males (25-49)                OR  
Females (25-49)                OR  
 Table A4.6 Condom use, and circumcision probability (continued) 
CONDOM USE, AND CIRCUMCISION PROBABILITY 
 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 
 
Assumption
Males (50+)                OR  
Females (50+)                OR  
rcumcision 
probability 
FSW Clients 
               
OR 98 
MSM 
               
OR 98 
Drug Users 
               
OR 98 
Prisoners 
               
OR 98 
Military                OR 98 
Children                OR 97 
Male Youth               97 OR  
Males (25-49)               98 OR  
Males (50+) 
              
98 OR  
  Non-HIV deaths, STIs and TB prevalence (percentage)  
HIV DEATHS, STIS AND TB PREVALENCE (PERCENTAGE) 
  2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 
People die 
related 
causes per 
FSW 1.09 1.05 1.02 0.98 0.95 1.13 1.07 1.03 1.00 0.96 0.88 0.85 0.82 0.79 
FSW Clients 0.58 0.56 0.54 0.52 0.50 0.59 0.56 0.54 0.52 0.50 0.46 0.45 0.43 0.41 
MSM 0.58 0.56 0.54 0.52 0.50 0.59 0.56 0.54 0.52 0.50 0.46 0.45 0.43 0.41 
Drug Users 0.87 0.83 0.80 0.77 0.74 0.88 0.84 0.81 0.78 0.75 0.69 0.67 0.64 0.62 
Prisoners 1.15 1.11 1.07 1.03 0.99 1.17 1.12 1.08 1.03 0.99 0.93 0.89 0.86 0.83 
Military 0.48 0.46 0.45 0.44 0.43 0.45 0.44 0.43 0.42 0.41 0.34 0.34 0.33 0.32 
Children 1.37 1.34 1.32 1.29 1.26 1.15 1.12 1.09 1.06 1.03 0.92 0.90 0.87 0.85 
Male Youth 0.48 0.46 0.45 0.44 0.43 0.45 0.44 0.43 0.42 0.41 0.34 0.34 0.33 0.32 
Female Youth 0.47 0.46 0.45 0.44 0.43 0.46 0.45 0.44 0.43 0.42 0.35 0.34 0.34 0.33 
Males (25-49) 0.58 0.56 0.54 0.52 0.50 0.59 0.56 0.54 0.52 0.50 0.46 0.45 0.43 0.41 
Females (25-49) 0.54 0.53 0.51 0.49 0.47 0.56 0.53 0.52 0.50 0.48 0.44 0.42 0.41 0.40 
Males (50+) 4.19 4.09 4.00 3.91 3.82 4.12 4.08 3.98 3.89 3.79 3.83 3.72 3.62 3.51 
Females (50+) 3.94 3.85 3.77 3.68 3.59 3.86 3.77 3.68 3.59 3.49 3.47 3.37 3.26 3.16 
 
  Non-HIV deaths, STIs and TB prevalence (percentage) (continued) 
HIV DEATHS, STIS AND TB PREVALENCE (PERCENTAGE) (CONTINUED) 
 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 Assumption
People die 
related 
causes per 
FSW               26.0 OR 
FSW Clients                OR 5.9
MSM              1.4  OR 
Drug Users                OR 3.9
Prisoners                OR 3.9
Military                OR 3.9
Children                OR 0.0
Male Youth               1.1 OR 
Female Youth               8.8 OR 
Males (25-49)               2.0 OR 
Females (25-49)               10.7 OR 
Males (50+)               0.5 OR 
Females (50+)               7.1 OR 
Prevalence of 
discharging 
FSW            62   42 OR 
FSW Clients                OR 6.8
MSM                OR 6.1
Drug Users                OR 3.1
Prisoners                OR 5.1
Military                OR 3.1
Children                OR 
Male Youth               1.5 OR 
Female Youth               11.8 OR 
  Non-HIV deaths, STIs and TB prevalence (percentage) (continued) 
HIV DEATHS, STIS AND TB PREVALENCE (PERCENTAGE) (CONTINUED) 
Males (25-49)             10.6 10.0 2.0 OR 
Females (25-49)               12.0 OR 
Males (50+)               2.3 OR 
Females (50+)               8.3 OR 
Tuberculosis 
prevalence 
FSW              0.3  OR 
FSW Clients                OR 0.1
MSM                OR 0.1
Drug Users                OR 0.1
Prisoners              0.5  OR 
Military                OR 0.1
Children                OR 0.1
Male Youth                OR 0.1
Female Youth                OR 0.1
Males (25-49) 0.1          0.1  0.1 0.1  OR 
Females (25-49) 0.1          0.1  0.1 0.1  OR 
Males (50+)                OR 0.1
Females (50+)                OR 0.1
 
  Injecting drug use parameters 
INJECTING DRUG USE PARAMETERS 
  2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014  Assumption
number of  
ions per 
person per year 
FSW                OR  
FSW Clients                OR  
MSM                OR  
Drug Users            6.5    OR  
Prisoners                OR  
Military                OR  
Children                OR  
Male Youth                OR  
Female Youth                OR  
Males (25-49)                OR  
Females (25-49)                OR  
Males (50+)                OR  
Females (50+)                OR  
Average % of 
people who 
receptively 
needle/syringe 
 
FSW                OR  
FSW Clients                OR  
MSM                OR  
Drug Users            24    OR  
Prisoners                OR  
 
  Injecting drug use parameters (continued) 
INJECTING DRUG USE PARAMETERS 
 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 Assumption
Average % of 
people who 
receptively 
needle/syringe 
 
Military                OR 
Children                OR 
Male Youth                OR 
Female Youth                OR 
Males (25-49)                OR 
Females (25-49)                OR 
Males (50+)                OR 
Females (50+)                OR 
 Transitions 
TRANSITIONS 
 FSW 
FSW 
clients MSM 
Drug 
Users Prisoners Military Children 
Male  
Youth 
Female  
Youth 
Males  
(25-49) 
Females 
(25-49) 
Males 
(50+) 
Females 
(50+)
related 
transitions 
number of 
years before 
movement) 
FSW             
FSW Clients             
MSM             
Drug Users             
Prisoners             
Military             
Children        30 30    
Male Youth          10   
 
  Transitions (continued) 
TRANSITIONS 
 
FSW 
FSW 
clients MSM 
Drug 
Users Prisoners Military Children 
Male  
Youth 
Female  
Youth 
Males  
(25-49) 
Females 
(25-49) 
Males 
(50+) 
Females 
(50+)
related 
transitions 
number of 
years before 
movement) 
Female Youth           10  
Males (25-49)            25 
Females (25-49)             
Males (50+)             
Females (50+)             
related 
transitions 
number of 
years before 
movement) 
FSW           18  
FSW Clients            40 
MSM             
Drug Users          28   
Prisoners          2.5   
Military          25   
Children             
Male Youth             
Female Youth             
Males (25-49)             
Females (25-49)             
Males (50+)             
Females (50+)             
 
 10 Partnerships 
PARTNERSHIPS 
 
FSW 
FSW 
clients MSM 
Drug 
Users Prisoners Military Children 
Male 
Youth 
Female 
Youth 
Males  
(25-49) 
Females 
(25-49) 
Males 
(50+) 
Females 
(50+)
Interactions 
FSW             
FSW Clients 1        5  5  
MSM   5      1  2  
Drug Users         1  2  
Prisoners             
Military         1  2  
Children             
Male Youth 1        3    
Female Youth             
Males (25-49) 1        3  6  
Females (25-49)             
Males (50+)           1  
Females (50+             
Interactions FSW             
FSW Clients 1        5  3  
MSM   7.5      1  1  
Drug Users         1  1  
Prisoners     1        
Military         1  1  
Children             
Male Youth 1        5    
Female Youth             
 
 Table A4.10 Partnerships (continued) 
PARTNERSHIPS 
 
FSW 
FSW 
clients MSM 
Drug 
Users Prisoners Military Children 
Male 
Youth 
Female 
Youth 
Males  
(25-49) 
Females 
(25-49) 
Males 
(50+) 
Females 
(50+)
Males (25-49) 1        5  3  
Females (25-49)             
Males (50+)           1  
Females (50+)             
Interaction 
commercial 
FSW             
FSW Clients 1            
MSM   1          
Drug Users             
Prisoners             
Military 1            
Children             
Male Youth             
Female Youth             
Males (25-49)             
Females (25-49)             
Males (50+)             
Females (50+)             
Interaction 
people who 
inject drugs 
FSW             
FSW Clients             
MSM             
Drug Users    1         
Prisoners             
 Table A4.10 Partnerships (continued) 
PARTNERSHIPS 
 
FSW 
FSW 
clients MSM 
Drug 
Users Prisoners Military Children 
Male 
Youth 
Female 
Youth 
Males  
(25-49) 
Females 
(25-49) 
Males 
(50+) 
Females 
(50+)
Military             
Children             
Male Youth             
Female Youth             
Males (25-49)             
Females (25-49)             
Males (50+)             
Females (50+)             
